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University of California San Diego, 2020 
San Diego State University, 2020 
 
Professor Tom Huxford, Chair  
 
 Antibodies are a class of proteins that are secreted from our immune system to neutralize 
pathogens. They are very specific to the target cells and stably folded therefore they have become 
engaging for many scientists for decades. We were interested to study a novel group of antibodies 
that interacts to metals. Our findings indicated that metals are effective on stabilizing the antigen: 
antibody interaction. Previously, we were able to crystallize LT1009 antibody which is a 
humanized version of murine LT1002 IgG antibody. The crystal structure indicated that LT1009 
employs two bridging calcium ions in the binding site to antigen. The biologically active lipid 
xx 
sphingosine-1-phosphate (S1P) was the antigen.  
Flame atomic absorption spectroscopy (FAAS) confirmed that murine LT1002 also binds 
calcium in solution and inductively coupled plasma-mass spectrometry (ICP-MS) indicates that, 
although calcium is the preferred metal binding cofactor, LT1002 can also bind to magnesium and 
to a much lesser extent, barium.  Isothermal titration calorimetry revealed that LT1002 binds two 
calcium ions endothermically with dissociation constants in the high μM range. Finally, an 
engineered, recombinantly expressed and purified antibody Fab fragment consisting of the murine 
germ-line encoded light and heavy chain genes from which LT1002 is likely derived and exhibits 
calcium binding profile as the mature antibody. 
Furthermore, we were interested to apply other metal bindings to the precursor 
metalloantibody. Therefore, we designed a large scale expression method to express the precursor 
antibody in Sf9 cells. Then, we were interested to design a plasmid by using site directed 
mutagenesis to change the key residues that were involved with the binding sites of Ca2+ and 
antigen. After that we were able to express and purify mutant antibody but this time the new 
metalloantibody binds to Zn2+. Engineered zinc antibodies can have the potential for site specific 
conjugation. Moreover, Zn2+ can protect cysteine from oxidation at the binding site.  We propose 
that LT1002 is representative of a class of naturally occurring metalloantibodies that are 
evolutionarily conserved within the genomes of mammalian species.
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Introduction 
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1. Properties of antibodies  
 
Antibodies are the most useful and profitable biological resources in biotechnology and 
pharmaceuticals. Monoclonal antibodies are the leaders of biological therapeutics due to their 
epitope specificity (Espiritu, Collier, and Bingham 2014). Biologic therapeutics, like antibody 
drugs, target specific cancer cells and kill the unhealthy cells instead of chemotherapeutics that 
have an effect on all healthy cells. Nowadays, a few antibody drug conjugates have gotten the 
approval form FDA (Food and Drug Administration) and the rest of the drugs are under 
development (Bajorath 2015).  
Antibodies are proteins secreted from B cells of our adaptive immune cells to neutralize 
pathogens, such as viruses and bacteria.  They are critical for immunity against infectious 
diseases, and extensively used for prevention and treatment of infection caused by bacteria, 
virus, and other infectious agents to improve public health. Antibodies recognize a unique part of 
the pathogens called antigens with their fragment antigen binding (Fab) variable region and the 
part of the antigen that antibodies bind to is called epitope (Janeway and Travers 1994; Litman et 
al. 1993; Maverakis et al. 2015).  
Emil von Behring was awarded the first Nobel Prize in Physiology or Medicine in 1901 
for his discovery of serum therapy for diphtheria. This led to the term antitoxin and later named 
as “antikörper” translated to “antibody” by Paul Erlich in a 1891 paper (Graham and Ambrosino 
2015).  
The advantage of antibodies is their high effectiveness when compared to small molecule 
drugs. They usually react highly specific against one target, which results in less undesirable side 
3 
effects and low toxicity. A major barrier for the success of biologics, especially peptide and 
protein drugs, has been their lack of oral absorption. Recently, new delivery systems have been 
developed to overcome this disadvantage. Another barrier of biologics has been the transition of 
antibody candidates from academic to industrial research, which stems from difficulties in large 
scale production of biotechnological products. Compared to the production of small molecules, 
antibodies production is highly complex. For example, antibodies therapeutics are produced in 
living cells, so they require several post-translational modifications to enhance their specificity 
and complex purification processes to ensure their safety (Ecker, Jones, and Levine 2015).  
1.1. Structures of antibodies 
Antibodies (Ab), also known as immunoglobulins (Ig), are proteins secreted mainly 
by plasma B cells that is used by the immune system to neutralize pathogens, such as pathogenic 
bacteria and viruses (Jackson and Thomas 2013). Antibodies are built from four polypeptide 
chains. They consist of two identical heavy chains (H chains) and two identical light chains (L 
chains), which assemble into a structure that looks like the Y shape. An IgG molecule has a 
molecular weight of about 150 kDa, each heavy chain is approximately 50 kDa and each light 
chain is approximately 25 kDa. Each arm of the Y is made up of a complete light chain paired 
with the amino-terminal part of a heavy chain, covalently linked by a disulfide bond. The stem of 
the Y consists of the paired carboxy-terminal portions of the two heavy chains. The two heavy 
chains are also linked to each other by disulfide bonds.  
Heavy and light chain each consists of a series of similar sequence motifs; a single motif 
is about 100–110 amino acids long and folds up into a compact and exceptionally stable protein 
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domain, called an immunoglobulin domain. The V region at the amino-terminal end of each 
heavy or light chain is composed of a single variable domain (V domain):  A VH and a VL 
domain together form an antigen-binding site. The other domains have little or no sequence 
diversity and are called the constant domains (C domains), which make up the C regions. The 
constant region of a light chain is composed of a single CL domain, whereas the constant region 
of a heavy chain is composed of three or four CH domains, depending on the isotype. The γ 
heavy chains of IgG, IgD, and IgA have three domains—CH1, CH2, and CH3. IgM and IgE also 
have a fourth C domain—CH4. Four different IgG subclasses include: IgG1, IgG2, IgG3, and 
IgG4 (T. Sharma and Gupta 2019). They differ in the constant region of the heavy chain and in 
the hinge. Furthermore, two β sheets are held together by strong hydrophobic interactions 
between their constituent amino acid side chains (the filling). The structure is stabilized by a 
disulfide bond between the two β sheets. The three hypervariable loops are called 
complementarity-determining regions (CDR1, CDR2, and CDR3) because they provide a 
binding surface that is complementary to the antigen (Sutton et al. 2019).  
There are three antibody chromosomal locations in human: the heavy-chain locus on 
chromosome 14, the κ light chain locus on chromosome 2, and the λ light-chain locus on 
chromosome 22. Different gene segments encode the leader peptide (L), the V region (V), and 
the constant region (C) of the heavy and light chains. The light chain variable domain consists of 
V and J (joining) gene segments and the constant domain includes C gene segments. The heavy 
chain variable domain contains V, D (diversity) and J, while the constant domains of the heavy 
chain includes CH1, CH2 and CH3 gene segments. Diversity between V gene segments are in the 
sequences that encode CDR1 and CDR2 of the V domain. CDR3 is determined by the sequence 
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difference introduced at the junction between the V and J segments (Cook 2000). 
1.2. Humanization of antibodies 
Antibodies have emerged as effective tools in the treatment and diagnosis of different 
human diseases. Non-human antibodies have been demonstrated to induce human immune 
responses, which result in neutralization of administered antibody and limits the application of 
such antibodies in the treatment of human diseases. To overcome this problem, the technology of 
antibody humanization has been developed. Antibody humanization is an efficient approach to 
eliminate or reduce the immunogenicity of these antibodies (Adamkewicz, Kiialainen, and Paz-
Priel 2019). The complementarity determining regions (CDRs) are responsible to bind to a 
specific antigen. CDR grafting is a humanization technique whereby humanized antibody 
sequences are generated by selecting the CDRs of the original antibody (usually murine, but 
increasingly other species are being humanized, including rabbits) and grafting them into a 
human framework (Buick 2016).  
In our studies, we used LT1009 antibody, which is a humanized monoclonal antibody 
and we studied its crystal structure. LT1009 binds specifically to lipid sphingosine-1-phosphate 
(S1P).  S1P has an effect in heart disease and cancer (J. M. Wojciak et al. 2009).  
Another example of humanized monoclonal antibody that has shown promising results to 
treat Alzheimer by engineering of antibody using the CDR-grafting method has been published. 
Both humanized scFv (single chain variable fragment) and Fab fragments have great affinity in 
the range of low nanomolar for Aß1–16 peptide. Aß peptide is generated from the proteolytic 
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cleavage of amyloid plaques, which causes Alzehmer (an effective target for therapy). 
Interestingly, in vitro humanized antibody fragments were able to inhibit amyloid fibril 
formation, oligomer mediated neurotoxicity, and disaggregating preformed amyloid fibrils 
(Robert et al. 2010).  
Furthermore, omalizumab is a humanized recombinant monoclonal anti-IgE antibody 
treats allergic diseases and it has been effective on adult patients with moderate-to-severe 
allergic asthma. The anti-IgE antibody inhibits free IgE from blood serum to bind to cellular 
receptors. By reducing IgE levels and IgE receptor expression in blood serum, inflammatory 
cells in the context of allergic reduces. Omalizumab therapy is well tolerated and effectively 
improves symptoms, reducing asthma exacerbations and the need to use high dosage of inhaled 
corticosteroids to control diseases. In addition, omalizumab improves quality of life of patients 
with severe allergic asthma that is inadequately controlled by currently available asthma 
medications. In conclusion, omalizumab represents an approach to the treatment of asthma and 
may help an important need in patients with moderate-to-severe asthma (Gennaro et al. 2007).  
1.3. B cells activation and affinity maturation 
Circulating B cells that do not have antigens are known as naive B cells. They express 
both IgM and IgD on their surfaces, which are the only immunoglobulin isotypes that are 
expressed simultaneously by a B cell. Once the antigenic peptide is taken by the B cell through 
receptor mediated endocytosis, it must appear at the cell surface in order to bound to the antigen-
specific T cell receptor. This is accomplished by binding the peptide to a membrane-associated 
protein inside the cell, then carries the antigen to the cell surface. The human glycoproteins that 
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binds and transports peptide antigens to cell surface are called MHC molecules (major 
histocompatibility complex molecules). Only when a peptide has been bound to MHC molecule, 
it can travel from inside the cell to the surface. Antigen-specific CD4+ T-cell receptor can 
recognize the peptide antigen and MHC molecule. Interaction of the B cell with a T helper cell is 
necessary to produce full activation of the B cell and antibody generation following antigen 
binding (Reth et al. 2004).  
Interestingly, single-nucleotide substitutions (point mutations) happens when the B cell 
gets activated by the antigen. B cells bearing these mutant high-affinity immunoglobulin 
receptors compete most effectively for binding to antigen and are preferentially selected to 
mature into antibody-secreting plasma cells. The changes are concentrated at positions in the 
heavy-chain and light chain of the CDR loops that form the antigen-binding site and directly 
contact antigen. This process is called affinity maturation which is an evolution that variant 
immunoglobulins generated in a random manner are selected for the purpose of improving 
binding to the antigen. This capacity for extraordinarily rapid evolution in pathogen-binding 
immunoglobulins is helpful for human immune system to catch up with the generally faster-
evolving pathogens (Shehata et al. 2019).  
1.4. Monoclonal antibody  
A single species of immunoglobulin molecules is produced by culturing a single clone of 
a hybridoma cell. MAbs recognize only one chemical structure, i.e., they are directed against a 
single epitope of the antigenic substance used to raise the antibody (Morrow and Felcone 2004). 
The first commercial development of therapeutic monoclonal antibodies is, Orthoclone OKT3, 
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was approved for prevention of kidney transplant rejection. Since the approval of OKT3, 
therapeutic monoclonal antibodies and antibody- related products, such as Fc-fusion proteins, 
antibody fragments, and antibody-drug conjugates (collectively referred to hereafter as 
monoclonal antibody products) have grown to become the dominant product class within the 
biopharmaceutical market (Patterson 2005).   
1.4.1 Applications of monoclonal antibodies 
Monoclonal antibody are approved for the treatment of a variety of diseases, ranging 
from those that treat patient populations of a few thousand or less for such orphan indications as 
paroxysmal nocturnal hemoglobinuria or the cryopyrin associated periodic syndromes to those 
treating hundreds of thousands of patients for some cancers and multiple sclerosis or even 
millions of patients for diseases such as asthma and rheumatoid arthritis (Ecker, Jones, and 
Levine 2015). 
1.4.2 Therapeutic properties 
Antibody-mediated therapy utilizes antibodies that have the ability to bind specifically to 
certain cells or proteins with high affinity. The advantages of antibodies as therapeutics are: it is 
stably folded; it is specific to the target site; and it can clear by the body’s natural immunological 
processes when the antibody has bound to its target. One of the advantages to develop antibody-
conjugated therapies (ACTs) is to use mAbs to deliver potent therapeutic agents directly into 
tumor cells expressing cancer-specific antigens. This can cause less exposure of normal tissues 
and reduce toxicity compared to chemotherapy (Parakh et al. 2016). A monoclonal antibody 
(Avastin) is able to directly stop certain tumor growth by binding to VEGF (vascular endothelial 
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growth factor). VEGF can go through mutations; therefore, Avastin can be ineffective at 
removing VEGF (Motzer and Bukowski 2006).  
1.5. Antibody engineering 
In 1997, the first engineered antibody was approved by the US Food and Drug 
Administration (FDA). It was a murine monoclonal antibody that binds to tumor-specific 
antigens and could differentiate cancer cells from healthy cells. After that, more than 300 
programs for the development of therapeutic antibodies have been described in industrial and 
academic laboratories. The development of antibodies is now very critical to cure several notable 
pathogenic diseases. They can defend against transmissible diseases or completely eliminate an 
infection. Polyclonal antibodies contain varying concentrations of different antibodies, and as 
such are not commonly used clinically. Conversely, monoclonal antibodies are highly specific, 
permitting more enhanced clinical diagnostics (Filpula 2007). In my research, I have engineered 
monoclonal antibody to enhance the binding of the antibody to different antigens followed by 
greater affinity binding. Nowadays, human antibodies are generated in vitro by antibody 
engineering technologies, such as phage display, construction of antibody fragments, 
immunomodulatory antibodies, and cell-free systems (Edwards and He 2012).  
1.5.1 Single Chain Variable Fragment (ScFv) 
Single chain variable fragment has great affinity, solubility, and binding specificity to 
antigen and has been used for antibody engineering, biotechnology, cancer research, and 
biomedical applications. ScFv is constructed by a peptide linker that binds the heavy chain to 
light chain of immunoglobulins. Engineered ScFv enhances the effective functions of full-length 
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antibodies. It can also carry toxins to kill cells, or cytokines to activate the immune system. 
Moreover, multiple target sites can bind to bispecific antibodies (AlDeghaither, Smaglo, and 
Weiner 2015). Recombinant antibody expression and engineering has eased the expression of 
antibody fragments in bacteria (E. coli), as well as mammalian (Chinese hamster ovary (CHO), 
or myeloma cell lines e.g., Sp2/0), yeast (Pichia pastoris), plant (Arabidopsis), and insect cells 
(Drosophila melanogaster) (Frenzel, Hust, and Schirrmann 2013). The benefits of smaller 
fragments over full length antibodies are better tumor and tissue penetration, blood clearance, 
short retention times. In addition, they have better fusion in bacteria, and display on filamentous 
phage (Saeed et al. 2017).  
1.5.2 Engineered Immunomodulatory Antibodies 
Immunomodulatory techniques are adjustment of the immune system in order to increase 
the clinical efficacy of therapeutic antibodies. Overexpressed or mutated cell surface antigens are 
target for modulated antibody based drugs. This technology developed on engineering the 
antigen or receptor of the immune system, changing the Fc function and T cell activation and 
antibody drug conjugates (ADC) targeting a specific antigen. Immunomodulatory antibodies 
have been successful in clinical studies (Scott, Wolchok, and Old 2012).  
Development of antibody drug conjugates (ADCs) has been effective to treat infectious 
diseases and target cancer cells. ADCs are being processed by antibody generation and contains 
a selection of highly cytotoxic molecules, and stable linkers that connects the payloads to the 
antibody (Vincent and Zurini 2012).  
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Site-specific conjugation strategy has been used for antibody-drug conjugates and 
employing metal binding motif is important for site specific conjugation. There are several site-
selective conjugation strategies to selectively label highly cytotoxic payloads onto antibodies, 
including enzymatic conjugation. The use of site-specific conjugation has significant advantages 
over conventional chemistry conjugations and is used for antibody-drug conjugates (ADCs). To 
enhance drug-to-antibody ratio (DAR) in order to have a better pharmacokinetics, (PK), 
disposition, and efficacy of the ADC, site-specific payload placement will control it. 
Furthermore, linker composition has also effect on an ADC properties. Drake et al. (2014) 
reported a novel site-specific conjugate to engineer aldehyde tags on antibody’s backbone. This 
chemistry provides stable C-C bond between the cytotoxin payload and the antibody which is 
more stable than the other linker chemistries used to generate ADCs. The flexibility and 
versatility of the aldehyde tag has impact on the conjugation site as well as the linker 
composition on ADC properties. In this paper, IgG was tagged with aldehyde on different 
locations on the IgG1 backbone and the characterization of product is being described. The site 
of the conjugation has efficacy and pharmacokinetic behavior in rodents. This benefit causes 
improved safety profile in rats as compared to conventional lysine conjugate (Drake et al. 2014).   
1.5.3. Nonconventional antibodies 
Single chain antibodies or nanobodies are a novel class of therapeutic proteins based on 
immunoglobulin single variable domains. Like a full length antibody, it can bind to antigen 
specifically. It has a molecular weight about 12-15 kDa. The immunoglobulin single variable 
domains may be derived from the variable domains of heavy chain-only antibodies that naturally 
occur in camelids. Compared to conventional antibodies, nanobodies are missing CH1 domain of 
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their heavy chain (Muyldermans 2013). The single heavy chain domain antibody were 
engineered from heavy chain domain found in camelids and it is called VHH fragments (Harmsen 
and De Haard 2007).  Furthermore, single variable heavy chain has also found in shark and 
Cartilaginous fishes, which are the oldest living organisms, and it is called immunoglobulin new 
antigen receptor VNAR fragment. Moreover, the Cartilaginous fishes and sharks have 4 and 5 
constant heavy domain in their Fc region respectively (Feige et al. 2014; Möller et al. 2010).  
The advantages of using nanobodies over full length antibodies are that nanobodies can 
penetrate into tissues for instance, crossing the blood brain barrier compared to conventional 
antibodies. They have uniques binding capacity to small cavities and have high affinity and 
specificity to antigens. Moreover, they are highly soluble with great rapid clearance in vivo. In 
contrast to conventional antibodies, nanobodies have high stability in different abnormal 
temperature and pH (Širochmanová et al. 2018; Morrison 2019; Rissiek, Koch-Nolte, and 
Magnus 2014). Although most of nanobodies are form heavy chain single variable domain, there 
are also reports on nanobodies derived from light chain single domain that can bind to antigen 
specifically (Ghannam et al. 2015).  
1.5.3.1 Bispecific nanobodies 
Bispecific antibodies have great therapeutic and diagnostic applications. They can 
recognize two different epitopes either from the same antigen or different antigens. Single 
domain antibodies, such as VHH and VNAR and nanobodies can be used to generate bispecific 
molecules. Combination of two or more single domain antibodies can make divalent, trivalent 
and multivalent molecules, which they can bind to specific epitopes (Brinkmann and 
Kontermann 2017). In a study, bivalent camel VHH domains have been fused with a linker that 
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has stability in serum and flexibility (Els Conrath et al. 2001). They used a linker which was 
derived from llama IgG2a upper hinge. Moreover, tetravalent bispecific VHH molecules were 
generated by liking four VHH, two directed against TcdA and two against TcdB.  
Antibiotic-associated diarrhea can be caused by Clostridium difficile and the causing 
agent is pseudomembranous colitis which is associated with inflammation of the colon. Two 
large exotoxins, TcdA and TcdB are the primary reasons for C. difficile infection (CDI). This 
bispecific nanobodies have shown neutralizing effect in vivo and in vitro (Yang et al. 2014).  
Moreover, nanobodies that neutralizes Pseudomonas aeruginosa has been discovered. 
Large and random formatting library of bivalent and biparatopic (combinations of two different) 
nanobodies to study the blockage of Pseudomonas aeruginosa has been explored. PcrV is an 
important part of the type III secretion system (T3SS). Its oligomeric nature provides several 
bindings and blocking options. Screening the library showed several promising biparatopic 
options for nanobody building block. Best potencies were certified with further characterization 
in two different P. aeruginosa T3SS-mediated cytotoxicity assays. Three biparatopic nanobodies 
confirmed 100% survival with using prophylactic and reducing lung P. aeruginosa burden of 
lethal mouse by up to 2 logs. At a very low doses it protected mice from infection related 
changes in lung. At last the process of screening such libraries for potency improving is useful 
for other target and therapeutic platforms (Tavernier et al. 2016).  
We have crystallized PcrV with two monovalent VHH nanobodies and solved the 
structure for the first time. In Chapter III we will further discuss T3SS secretion system, PcrV, 
and the methods used to crystallize the complex.  
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2. Metals in biology  
One-third of all proteins are expected to be metalloproteins (Waldron and Robinson 
2009). Therefore, they have different applications in cell, for example storage and transport of 
proteins, enzymes and signal transduction proteins, or infectious diseases (Marmion 2014). It can 
also get involved in electron transfer reactions (cytochromes), may act as storage (e.g., ferritin 
for iron) or transport proteins (e.g., transferrin for iron). In the latter groups of proteins, the metal 
storage is reversible and the metal is a temporary component (Sigel and Pyle 2007).  
The relative amount of metalloproteins could be inherent to the amino acid sequence of 
the proteins. However, the use of metals by antibodies to recognize and bind to antigens is still 
somewhat of a novelty.  
2.1. Metalloproteins 
One of the most common metalloproteins is zinc finger, which is a small protein motif 
that is recognized by the coordination of one or more zinc ions (Zn2+) in order to stabilize the 
fold (Klug and Rhodes 1987). The crystal structures of zinc finger-DNA complexes solved in 
1991 and 1993 indicated the canonical pattern of interactions of zinc fingers with DNA. The 
binding of DNA to protein is different from what was expected and is not through the 2-fold 
symmetry of the double helix, instead zinc fingers are linked linearly in tandem to bind nucleic 
acid sequences of varying lengths (Pavletich and Pabo 1991). Zinc finger proteins (ZNFs) have a 
wide range of applications. It can interact with DNA, RNA and other proteins. Therefore, ZNFs 
are involved in transcriptional regulation, ubiquitin- mediated protein degradation, signal 
transduction, actin targeting, DNA repair, cell migration, and numerous other processes 
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(Cassandri et al. 2017).  
Moreover, specific metal binding properties of monoclonal antibody to metal-EDTA 
complexes has been studied by Blake et al. (1996). This monoclonal antibody that recognizes 
cadmium-EDTA complexes covalently coupled to a carrier protein. The quality of the antibody 
to recognize 16 different metal-EDTA complexes was evaluated using KinExATM immunoassay 
instrument. The dissociation constant of the antibody to cadmium and mercury-EDTA 
complexes was 21 and 26 nM, respectively. Other metal-EDTA complexes tested includes, 
Mn(II), In(III), Ni(II), Zn(II), Co(II), Cu(II), Ag(I), Fe(III), Pb(II), Au(III), Tb(III), Ga(III), 
Mg(II), and Al(III) bound and their affinities were from 20- to 40,000-fold less than determined 
for the cadmium-EDTA complex. The binding of divalent metal-chelate complexes correlates to 
the size of the metal ion, mercury and magnesium are exceptions here. The amino acid variable 
regions of the heavy and light chains were deduced from polymerase chain reaction 
amplification and subsequently used to construct models for the antigen binding regions. The key 
residue for the cadmium binding appeared to be His96 in the heavy chain (Blake et al. 1996). 
Furthermore, a monoclonal antibody that can detect uranium (VI) has been reported 
recently. The groundwater contamination with uranium has been the subject of concern these 
days. Uranium toxicity can cause lots of health problems such as renal failure, genotoxicity and 
cancer. The usual methods for detecting uranium were time-consuming, expensive non-portable 
equipment and the detection were not observed in-filed unless the water samples were analyzed. 
Moreover, the other methods available do not have quantitative analysis and the detection limit is 
not low enough to be in the range of recommendations for drinking water (30 ppb or 126 nM of 
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uranium). For the first time in this research sensitive paper-based biosensor strip has been 
introduced by Quesada-González et al. (2018) which includes U(VI) selective gold nanoparticle-
based lateral flow strips. This method is portable, fast, cheap and the detection limit is 36 nM 
which is lower than the action level (126 nM) established by the World Health Organization and 
the U.S. Environmental Protection Agency for drinking water.  The antibody gold nanoparticles 
enhance high sensitivity and are biocompatible to antibody. Antibody can recognize soluble U 
complexes with DCP (2,9-dicarboxyl-1,10-phenanthroline) chelator. This assay has a limit of 
detection of 36.38 nM, which is because of the small size of the U(VI)-DCP complex. This 
research can perform in situ and the results only takes 20 minutes. The strips can do both 
qualitative and quantitative analysis by using a mobile phone application (Quesada-González et 
al. 2018).   
The metal binding ion motif site-specific conjugation strategy has been reported by 
Chung, Lee, and Park (2016). Cysteine containing motifs as single repeat or tandem repeat were 
investigated. The tandem repeat of cysteine-glycine-histidine (CGH) metal binding motif has 
demonstrated binding to Co (II) ions suggesting that conformational transition of peptide was 
affected by the sequential metal ion binding. The free thiol reduction after reduced by reducing 
reagents illustrated strong retardation of cysteine oxidation in the order of Zn (II)>Ni (II)>Co 
(II). The metal binding motif CGH was cloned to the C-terminus of the antibody heavy chain and 
the ion-dependent oxidation characteristics were investigated. CGH-motif-introduced antibody 
showed strong dependence to the metal binding protect against oxidation. The cysteine reactivity 
for 22 hours with saturating O2 condition retained when the Zn (II) saturated antibody with 
tandem repeat of CGH motifs presented. Fluorophore labeling indicated that metal binding motif 
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can be used as an efficient tool for site-specific conjugation. Whereas, Trastuzumab without the 
tandem repeat of CGH motif showed non-specific dye conjugation. Zn (II) ion binding with the 
CGH motif showed fluorophores were site-specifically conjugated to the heavy chain of the 
antibody. The future goal of this research is to propose a method for strong metal ion dependence 
on oxidation protection and highly site-selective and specific conjugation for proteins that have 
multiple intrinsic cysteine like antibodies (Chung, Lee, and Park 2016).   
2.2. Metalloenzymes 
Metalloenzymes are protein enzymes that contain metal ions (metal cofactors), which are 
either directly bound to the protein or to the enzyme-bound nonprotein components (prosthetic 
groups). About one-third of all enzymes known so far are metalloenzymes. Also ribozymes, i.e., 
RNA molecules with enzyme function may contain structurally and/or functionally important 
metal ions (mostly divalent metal ions such as Mg2+) (Sigel and Pyle 2007).  
Recent publication on metalloprotease by Jennings et al. (2018) concluded that GtgA, 
GogA and PipA zinc metalloprotease effector proteins from type III secretion system are 
translocated into the host cell during Salmonella infection. They can cleave subunits of NF-κB 
(κ-light-chain-enhancer of activated B cells), therefore, suppressing host immune system. GtgA, 
GogA and PipA cleave p65, RelB and cRel subunits of NF-κB, whereas effector protein NleC of 
enteropathogenic and enterohemorrhagic Escherichia coli cleaved all five NF-κB subunits. 
Mutation results indicated that a single nonconserved residue in NF-κB1 and NF-κB2 that relates 
to Arg41 in p65 prevents cleavage of these subunits. This demonstrates the specificity of this 
enzyme cleavage. Crystal structure of apo-form of GtgA with p65 N-terminal domain valued the 
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importance of Arg41 residue. Furthermore, by mimicking the shape and negative charge of the 
DNA phosphate backbone GtgA can recognize NF-κB subunits. Moreover, structural based 
mutations explained the importance of GtgA key residues with p65 subunit which blocks NF-κB 
activation. This research provides detailed mechanism of substrate recognition by this family of 
proteins which is important for bacterial virulence (Jennings et al. 2018).  
Matrix metalloproteinases (MMPs) which includes collagenases, stromelysins, 
gelatinases, and membrane-anchored disintegrin metalloproteinases (ADAMs), and meprins are 
also structurally related zinc-dependent proteases family. These family initially was known to 
degrade extracellular matrix (ECM) but now it is known that has a wide range of biological and 
immune processes such as cellular development, adhesion, infiltration, activation and effector 
function, ligand–receptor interactions, cytokine, chemokine and growth factor activation, 
regulation of clotting factors, tissue damage, remodeling, and repair. Wide variety of cells 
secrete these metalloproteases which includes fibroblasts, myofibroblasts smooth muscle cells, 
epithelial cells, endothelial cells, neutrophils, macrophages, and lymphocytes. One of their major 
roles is to regulate the activation of cytokines like TNFα, chemokines, adhesion molecules, OX-
40, and Fas and others. Cytokines, growth factors, pathogen-associated molecular patterns 
(PAMPS), and damage-associated molecular patterns (DAMPS) can stimulate the activity of 
MMP. Dysregulation of MMP has so many effects such as inflammatory diseases; RA, MS, 
inflammatory bowel disease (IBD), asthma, pemphigus vulgaris (PV), atherosclerosis, ischemic 
stroke, and other neuroinflammatory diseases. Whereas, increased level of cytokines and other 
inflammatory pathways can cause excess of MMP release, uncontrolled degradation of the ECM, 
and tissue injury. As shown by Dübel and Reichert (2014), Key factor in causing colonic damage 
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could be because of expressed MMP-9 (gelatinase B) and MMP-2, in the gastrointestinal (GI) 
tract during IBD and being absent from the colonic epithelial in normal colonic tissue. 
Transgenic overexpression of MMP-9 in mice has shown increased epithelial cell proliferation 
and apoptosis. Furthermore, MMP-2 was shown to protect against tissue damage, whereas 
MMP-9 mediates tissue injury. However, significant side effects and lack of specific inhibitor in 
cancer clinical trial has urged the use of other precise gelatinase inhibitors that blocks both 
MMP-9 and MMP-2. Therefore, an anti-MMP-9 mAb could enhance this specificity and the 
optimal balance between efficacy and safety. Recently phase I of GS-5745 from Gilead Sciences 
Inc. a human IgG mAb, specific for MMP-9 for a solid tumor is ongoing (Dübel and Reichert 
2014).  
3. Metalloantibodies in nature 
 
Sphingosine-1-phosphate (S1P) is a signaling bioactive lipid that contributes in many 
signaling pathways. It has an important role in physiological processes, such as cell growth, 
differentiation, survival, and pathophysiological processes, such as cancer, cardiovascular 
disease, multiple sclerosis, neuropathic pain, involve S1P signaling (Gardell, Dubin, and Chun 
2006; Murph and Mills 2007; Skoura et al. 2007); (Tsai and Han 2016; Kawabata et al. 2018). In 
the sphingolipid signaling pathway, S1P has a key role and is produced from ceramide (CER) 
and sphingosine (SPH) with the kinase activity of  sphingosine (SPHK) (Milstien and Spiegel 
2006).  
In recent years, antibodies that target biologically active lipids have been studied as 
promising therapeutic agents. Previously, expression and purification of murine LT1002 and 
LT1009 the humanized version of LT1002 antibody was done. It has shown that both antibodies 
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bind to sphingosine-1-phosphate with high affinity and specificity and do not cross react with 
other structurally similar lipids (O’Brien, Jones, et al. 2009).  
Furthermore, Inductively-coupled plasma-mass spectrometry (ICP-MS) indicates that 
LT1002 binds to calcium, magnesium and, to a much lesser extent, barium (M. F. Erasmus 2012) 
(O’Brien, Jones, et al. 2009). Previously in our lab, a 1.9 Å X-ray crystal structure of humanized 
LT1009 Fab antibody version of the murine LT1002 anti-S1P antibody was determined. The X-
ray crystal data indicates the novel finding that it employs two bridging calcium ions in binding 
to its lipid antigen. Inductively coupled plasma-mass spectrometry (ICP-MS) indicates that 
LT1009 binds to calcium. The two calcium interact with aspartic acid residues from the CDR-L1 
and -L3 loops of the antibody variable light chain (VL) (Figure I.1) (J. M. Wojciak et al. 2009). 
Furthermore, the amino acids involved in metal coordination are encoded in the germ-line 
sequences of immunoglobulin kappa light chain genes within the genomes of diverse mammalian 
species and are included in several antibodies that have been previously analyzed.  
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Figure I.1 X-ray crystal structure of the LT1009 Fab: S1P complex.  The light chains are colored gold and the 
heavy chains are colored light brown. Bridging Ca2+ ions are grey spheres and S1P antigen is depicted as a ball and 
stick model (J. M. Wojciak et al. 2009). 
 
Interestingly, in another study X-ray crystal structure of variable domain antibody 
fragment (Fv) with mutant epidermal growth factor receptor (EGFRvIII) was solved. This 
antibody is called MR1 and binds specifically to EGFRvIII and not EGFR. Epidermal growth 
factor receptor is a membrane glycoprotein and is involved in protein tyrosine kinase activity. 
Many cancer cells such as breast and ovarian cancers, non-small cell lung carcinomas and 
prostate cancers have expressed receptor mutant, EGFRvIII. 1.8 Å X-ray crystal structure of 
MR1 disulfide stabilized Fv (dsFv) in complex with peptide antigen of the tumor cells was 
solved. It was the first time that the structure of MR1dsFv with synthetic peptide was 
characterized (Figure I.2). Furthermore, the CDR loops sequence of the light chain of the 
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antibody is similar to the CDRL1-L3 sequence of the metalloantibody that we studied. However, 
MR1 crystal structure is not indicating any metal in cooperation with the peptide. Moreover, the 
peptide binding site to the antibody is different from our metalloantibody binding site (Landry et 
al. 2001).  
 
Figure I.2 X-ray crystal structure of the MR1dsFv: synthetic peptide complex. MR1dsFv antibody domains are 
colored in green and cyan. Synthetic peptide is colored in purple. The CDR loops of the light chain sequence that are 
similar to our metalloantibody is represented as stick model and has yellow color (Landry et al. 2001).  
 
Previously, X-ray crystal structure of Q425 monoclonal antibody that protects against 
HIV has been discovered. CD4 is a glycoprotein found on the surface of immune cells such as T 
helper cells. CD4 with T helper cells are necessary for the human immune system. If CD4 
knocks out against untreated HIV infection or other immunosuppressive, the body will be 
resistless to a wide range of infection. CD4:Q425 can block viral entry but it does not interrupt 
the CD4: HIV-1 gp120 envelope glycoprotein binding. In this study, surface-plasma resonance 
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has shown that Q425 requires Ca2+ for recognition of CD4. Interestingly, calcium increases the 
affinity of Q425 to CD4 55,000-fold. X-ray crystal analysis data suggested that Q425 binds to 
CD4 in the presence of Ca2+ and Ba2+. This data suggests that Q425 held calcium has binding 
energy approximately 1.5 kcal/mol which is greater than usual protein atom. Indicating that 
metal ligation has significant role in antigen recognition (T. Zhou et al. 2005). Interestingly, the 
CDRL1-L3 sequences of Q425 is similar to our metalloantibody. However, the crystal structure 
indicates the presence of only one metal ion and the binding site of the CD4 to Q425 antibody is 
different from our metalloantibody (Figure I.3).  
 
Figure I.3 X-ray crystal structure of the Q425. Q425 antibody Fab domains are colored in green and cyan. DIDDD 
sequence is shown as sticks on the CDR loop1 and 3 of the light chain in yellow color. The orange sphere is 
indicating Ca2+ ion (T. Zhou et al. 2005).  
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In the presence of Ca2+, we have crystallized Fab fragment of humanized LT1009 anti-
sphingosine-1-phosphate antibody. The crystal structure shows that LT1009 binds to Ca2+ in the 
absence of antigen. The difference is the space between two Ca2+ ions are shorter in the presence 
of S1P and it is because of the electrostatic interaction of the oxygen ions on the phosphate group 
of sphingosine-1-phosphate. I will further discuss the crystal structure of humanized LT1009 
with Ca2+ and other homolog antibodies of LT1002 in different species in Chapter II.  
Moreover, other studies have shown the competition binding between carrier proteins and 
monoclonal anti-S1P and anti-LPA antibodies to sphingosine-1-phosphate (S1P) and 
Lysophosphatidic acid (LPA) lipids, respectively, where their dissociation constants (KD) values 
have been calculated. The competition binding analysis suggested the affinity of monoclonal 
anti-S1P is 102-103 times greater than the affinity of the carrier protein for individual LPA 
species (Jonathan K. Fleming et al. 2016). However, anti-LPA antibody (LT3015) shows no 
metal binding and the crystal structure confirms binding to Lysophosphatidic acid (LPA) 
independent of metals (J. K. Fleming et al. 2011).   
In order to study the chemical properties of this novel metalloantibody, we first must 
develop methods for recombinant expression and purification. We will then alter the residues 
observed to coordinate the Ca2+ ions and test their ability to bind more biochemically active 
metals.  It is expected that these novels, engineered metalloantibody scaffolds might serve as 
substrates for further development as a class of engineered metalloantibodies with the ability to 
be used as a site specific metalloantibody to conjugate to other drugs. This research is designed 
to identify other naturally occurring functional metalloantibodies and to test the hypothesis that 
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the use of metal coordination chemistry by antibodies to recognize their antigens is 
evolutionarily conserved in the mammalian immune system.  
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Chapter II  
 
Ion binding properties of a naturally 
occurring metalloantibody 
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1.Introduction 
At least one-third, and perhaps as many as one-half, of all functioning proteins are 
predicted to be metalloproteins (Thomson and Gray 1998)(Waldron and Robinson 2009)(Hu et 
al. 2014).  Included among these metal-dependent biological factors are the vast collection of 
diverse metalloenzymes, which includes many oxidoreductases, proteases, and all protein 
kinases, as well as metal-dependent extracellular receptors, signaling proteins, transcription 
factors, and charge transport complexes (Kretsinger, Uversky, and Permyakov 2013).  
However, the involvement of metals in antigen presentation and recognition by proteins 
of the adaptive immune system remains somewhat of a novelty.  In 2009, as part of an effort 
aimed at developing novel anti-inflammatory and potential anti-cancer antibody-based therapies 
that function by selectively binding to signaling lipids, we determined the X-ray crystal structure 
of the Fab fragment of a humanized mouse monoclonal antibody bound to its antigen 
sphingosine-1-phosphate (S1P) (O’Brien et al. 2009; Wojciak et al. 2009). The complex crystal 
structure revealed that the humanized anti-S1P antibody, known as LT1009 and derived from the 
murine anti-S1P antibody LT1002, employs two bridging Ca2+ ions that are required for antigen 
recognition and binding.  The two Ca2+ are partially coordinated within close proximity (<4 Å) 
of one another by three aspartic acid residues (Asp30-Asp31-Asp32) from light chain 
complementarity-determining region loop 1 (CDR-L1) and a fourth aspartic acid (Asp92) from 
CDR-L3.  This arrangement allows for one oxygen atom from the phosphate head group of S1P 
to complete a μ bridging bond to both bound Ca2+.  Subsequent in vitro analysis confirmed that 
the bound ions are indeed Ca2+ and characterization of the antibody:antigen complex by surface 
plasmon resonance (SPR) spectroscopy revealed the binding to be extremely favorable with a 
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dissociation equilibrium constant (KD) in the low nM range.  Removal of Ca2+, by addition of 
chelators such as EDTA or EGTA, as well as mutation of Ca2+-coordinating amino acid residues 
completely disrupted the complex to the same or even greater extent than did mutation of 
residues that contact the antigen directly. 
This direct observation of an antibody that was raised by immunization in mice 
employing interfacial bridging metal ions as a required component of its antigen recognition site 
called to mind several questions concerning the chemical nature of the anti-S1P antibody:Ca2+ 
interactions.  For example, can the antibody bind Ca2+ independently of antigen or is prior 
interaction with S1P a requirement for Ca2+ binding?  Does the antibody bind to metal ions other 
than Ca2+?  And, with what affinity is the Ca2+ bound?  It also raised questions about the biology 
underlying the anti-S1P antibody such as, did the metalloantibody develop its ability to bind to 
Ca2+ during the processes of somatic recombination and/or affinity maturation or is the potential 
to coordinate Ca2+ evolutionarily conserved within germline antibody gene sequences?  And, are 
there other examples of antibodies that employ Ca2+ or other metal ions in this fashion to 
recognize different antigens? 
In this study, we report results from a series of structural, in vitro biochemical, and 
protein engineering experiments that were performed in order to characterize the metal ion 
binding properties of the anti-S1P antibody and in order to test the hypothesis that Ca2+-mediated 
antigen binding is an evolutionarily conserved component of a complete and robust antibody 
repertoire.  Our results suggest that the anti-S1P antibody does not require antigen in order to 
bind Ca2+ and that the default Ca2+ binding mode is similar to that observed in the 
LT1009:Ca2+:S1P complex X-ray crystal structure.  We observe that the antibody binds Ca2+ 
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selectively, with an appreciable, but significantly lower capacity for binding Mg2+ and even 
lower affinity toward Ba2+.  We measure the Ca2+ binding affinity and find that its dissociation 
constant (KD) is an order of magnitude lower than the typical concentration of Ca2+ in plasma, 
suggesting that the anti-S1P antibody is preloaded with Ca2+ in vivo.  We identify the Ca2+ 
binding sequence in previously characterized antibodies, some, but not all, of which also require 
Ca2+ for binding to their respective antigens.  Finally, we observe that the amino acid sequence 
signature for Ca2+ binding is encoded for within the germline sequences of select antibody kappa 
light chain gene variable regions across diverse species and that an antibody Fab fragment 
expressing the mouse germline-encoded sequences from which the anti-S1P antibody is likely 
derived also binds to Ca2+ in solution.  These results strongly suggest that the Ca2+-dependent 
antigen binding observed in the anti-S1P antibody is an evolutionarily conserved and diversely 
applied component of a functional adaptive immune system. 
2. Materials and Methods 
2.1 DNA, oligos, plasmids 
Plasmids encoding murine (LT1002) and humanized (LT1009) anti-S1P antibodies have 
been described previously (O’Brien et al. 2009).  For construction of a shuttle plasmid containing 
both chains of the naïve germline-encoded Fab, we followed the previously reported protocols of 
Furuta, et al. (Furuta et al. 2010).  cDNA encoding the murine Ighv1-78 variable heavy chain in 
frame with Ighd1-1, Ighj2, and IgG1 constant heavy domain 1 with an N-terminal Gp64 signal 
peptide a C-terminal TEV protease-cleavable C-terminal hexa-histidine tag was synthesized with 
codons optimized for insect cell expression and containing 5'-EcoRI and 3'-HindIII sites and 
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introduced between EcoRV sites in a pUC57 plasmid (Genscript).  An analogous second pUC57 
plasmid was prepared containing a codon-optimized murine light chain gene fragment consisting 
of Igkv17-121 in frame with Igkj4 and the kappa gene constant light domain with N-terminal 
Gp64 signal sequence between 5'-NheI and 3'-SphI restriction sites.  Heavy and light chain 
cDNA were then prepared from the plasmids by double digestion with appropriate restriction 
enzymes and purified fragments were ligated into the corresponding restriction sites in the 
pFastBacDual plasmid (Thermo Fisher).  This arrangement places the heavy chain Fab under 
transcriptional control of the P10 promoter and expression of the light chain under the 
Polyhedrin promoter.   
2.2 Antibodies and Fab fragment generation 
Full length murine (LT1002) and humanized (LT1009) anti-S1P antibodies were 
produced in stable CD-CHO cell lines as previously described (O’Brien et al. 2009). Briefly, 
antibodies were purified by affinity chromatography on ProSep-vA-Ultra resin (Millipore).  Fab 
production from whole IgG has been described previously (Wojciak et al. 2009). Briefly, full 
length LT1009 IgG was digested at a 100:1 ratio with activated papain (Worthington); the 
reaction was quenched with iodoacetamide, dialyzed, and purified by anion exchange 
chromatography.  Fab-containing fractions were passed through a ProSep-vA-Ultra protein-A 
column, concentrated to 12 mg/mL, and stored at 4°C.  For preparation of recombinant naïve 
germline-encoded antibody Fab, we followed protocols for bacmid production, transfection of 
Sf9 insect cell monolayers, and recombinant baculovirus titer optimization that have been 
established in this laboratory and reported previously (Shaul, Farina, and Huxford 2008).  0.5 L 
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of media was prepared by centrifugation at 500 x g for 5 min. and vacuum filtration through 0.2 
μm nitrocellulose membrane (Millipore) and passed by gravity through 1 mL of Ni Sepharose 
Fast Flow resin (GE Healthcare) at 4°C.  The column was washed with 25 mM TRIS-HCl pH 
8.0, 150 mM NaCl, 25 mM imidazole and protein was eluted with wash buffer containing 150 
mM imidazole.  The eluted protein was treated with 0.1 M EDTA pH 8.0, filtered through 0.2 
μm syringe tip filter (Millipore), and purified on a SuperDex75 16/60 size exclusion 
chromatography column (GE Healthcare) in 25 mM TRIS-HCl pH 8.0, 150 mM NaCl.  Peak 
fractions were combined and concentrated to 5 mg/mL in 10 kDa molecular weight cutoff 
(MWCO) centrifugal concentrator (Millipore), flash frozen in liquid nitrogen, and stored at -
80°C. 
2.3 LT1009 Fab:Ca2+ complex formation and co-crystallization 
Crystals were grown by the hanging drop-vapor diffusion method at room temperature.  
Initial screening of for conditions that promote crystallization of antigen-free LT1009 Fab were 
identified by testing Crystal Screen I (Hampton Research) reagents supplemented with 10 mM 
CaCl2.  For optimal crystal growth, 1 μL of 12 mg/mL LT1009 Fab was mixed with 1 μL 
reservoir solution comprised of 0.1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) pH 7.5, 1.5 M Li2SO4, and 10 mM CaCl2 on a siliconized coverslip and sealed with 
high vacuum grease over 1 mL of reservoir solution.  Plate-like crystals of dimensions 0.3 × 0.3 
× 0.02 mm grew in 63 days at room temperature.  Crystals were harvested with nylon loops and 
immersed into 0.1 M TRIS-HCl pH 8.5, 0.2 M Li2SO4, 30% w/v polyethylene glycol 4000, 10 
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mM CaCl2, and 10% glycerol for approximately ten seconds prior to flash cooling in liquid 
nitrogen. 
2.4 X-ray crystallography 
Synchrotron data were collected at 100K on a NOIR-1 CCD detector at the Advanced 
Light Source Beamline 4.2.2, Lawrence Berkeley National Laboratory.  Diffraction data 
indexing and scaling of intensities were carried out with HKL2000 (Otwinowski and Minor 
1997).  Data collection statistics are presented in Table II.1.  Molecular replacement was 
performed via Phaser-MR in PHENIX using LT1009 Fab (PDB ID 3I9G) as a probe with ions, 
antigen, and solvent molecules removed and variable and constant domains separated, as 
described previously (King et al. 2017; McCoy et al. 2007).  Rigid-body and initial restrained 
maximum-likelihood refinements with all working data to 3 Å resolution and difference Fourier 
electron density map calculation to identify potential Ca2+ binding sites were carried out using 
REFMAC5 and FFT, respectively, in CCP4 (Murshudov, Vagin, and Dodson 1997).  Model 
building was completed in COOT (Emsley et al. 2010).  All further refinements were made in 
PHENIX (Adams et al. 2010).  Final assessment of the refined model was carried out using 
MolProbity (Chen et al. 2010).  Refinement statistics are presented in Table II.1.  Final atomic 
coordinates and structure factors were submitted to the Protein Data Bank (PDB ID: 6VRT).  
Figures were prepared using PyMOL (DeLano et al. 2002). 
2.5 Equilibrium dialysis 
Prior to testing, proteins were treated with 0.1 M EDTA pH 8.0 and purified either by 
dialysis (LT1002/LT3015 FAAS and ICP-MS experiments) or by size exclusion chromatography 
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(naïve germline-encoded Fab antibody ICP-MS).  200 μL of 100 mM stock solution of 
CaCl2·2H2O (EMD® #401800) prepared in 20 mM Na-HEPES pH 7.2., 20 mM NaCl was added 
to 1.8 mL of 1 mg/mL LT1002, 1 mg/mL LT3015, 1 mg/mL naïve Fab, or Na-HEPES buffer.  
The resulting solutions at 10 mM CaCl2 were applied to 3.5 kDa MWCO dialysis units (Slide-A-
LyzerTM MINI Dialysis Unit #88403).  In order to monitor the rate of equilibration, samples were 
dialyzed against 0.5 L of 20 mM Na-HEPES pH 7.2, 20 mM NaCl and analyzed at time points 0, 
1.5, 3.5, 7.5, and 22.5 hours.  In subsequent studies samples were dialyzed against Na-HEPES 
buffer for 24 hours with four changes of buffer.  Addition metals were tested by substituting with 
100 mM stock solutions of MgCl2·6H2O (VWR® #VW1483-01), SrCl2·6H2O (MP Biomedicals 
#9631K), BaCl2·2H2O (EMScience #43129930), Zn(C2H3O2)2·2H2O (Fisher Scientific® 
#053087), CdCl2 (MD Biomedical #8107K), MnCl2·4H2O (Fisher Scientific #041398), 
CoCl2·6H2O (Fisher Scientific® #040819), NiSO4·6H2O (EMDTM 35044548), CuSO4·5H2O 
(CAS 7758-99-8), YbCl3·6H2O (CAS 10035-01-05), GdCl3 (CAS 10138-52-0), and EuCl3·6H2O 
(CAS# 13758-92-7) in 20 mM Na-HEPES pH 7.2, 20 mM NaCl. 
2.6 Flame atomic absorption spectroscopy (FAAS) 
20 μL of sample solution was removed from the dialysis unit, treated nitric acid (5% final 
concentration), and heated at 98°C for 30 min. and centrifuged at 14,000 x g for 5 min.  Analysis 
was carried out on a 240 AA instrument (Agilent), which was calibrated by a 6-point dilution of 
1.0 ppm CaCO3 standard.  Instrument settings:  lamp current, 70% of 10 mA; compressed air, 9.0 
psi; burner height, 15 mm; burner position, 90°C; fuel flow, 1.1 L/min.; Ca2+ absorbance, 422.7 
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nm; slit width, 0.5 nm.  Between samples, the injection port was washed with 5.0% (v/v) HNO3 
solution. 
2.7 Inductively coupled plasma-mass spectrometry (ICP-MS) 
Samples were prepared as for FAAS and analyzed on an Agilent 4500 Series Inductively 
Coupled Plasma Mass Spectrometer (ICP-MS) through the Institute for Integrated Research 
Materials, Environments and Society at California State University, Long Beach. 
2.8 Isothermal titration calorimetry (ITC) 
A 20 mM CaCl2 solution was titrated at 2.0 μL increments into solutions of 300 μM 
LT1002, 300 μM LT3015, or no antibody in 50 mM Na-HEPES pH 7.2 and the bindings were 
measured on a MicroCal™ iTC200 instrument (Malvern) available through Protein Production 
and Analysis at the Sanford Burnham Prebys Medical Discovery Institute.  Data were analyzed 
by Origin™ software. 
2.9 Antibody sequence analysis 
Heavy and light chain variable domain light chain sequences were analyzed on the 
IgBlast server (http://www.ncbi.nlm.nih.gov/igblast) to identify naïve V, D, and J genes from 
which the LT1002 anti-S1P antibody is most likely derived (Ye et al. 2013). In order to identity 
antibodies with four Asp residues in CDR-L1 and -L3, a python function was applied to search 
for three neighboring Asp residues ([D][D][D]) in the abYsis database (Swindells et al. 2017).  
Output was analyzed by hand to identify whether the three Asp appeared in CDR-L1 and 
whether a fourth Asp was present in CDR-L3.  Identification of conserved kappa light chain gene 
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sequences in species other than mouse was performed by Blast (http://blast.ncbi.nlm.nih.gov) 
search with murine Igkv17-121 gene sequence (Madden, Tatusov, and Zhang 1996). 
3. Results  
 
3.1. X-ray crystal structure of a Ca2+-bound to Fab fragment in the absence of antigen 
We first analyzed whether the anti-S1P antibody is capable of binding Ca2+ in the 
absence of S1P or, alternatively, if their interaction is dependent upon the presence of antigen 
(Figure II.1).  We also wished to determine by what mode the antibody might bind Ca2+ in the 
absence of antigen.  This second question arose from our analysis of the results from a previous 
study in which X-ray crystallography was employed to determine the site of Ca2+ binding by the 
murine Q425 antibody.  Q425 selectively binds to the extracellular portion of the human CD4 
co-receptor in a Ca2+-dependent manner that inhibits steps subsequent to virus binding and 
protects against HIV infection of CD4+ T cells (Healey et al. 1990).  By crystallizing and 
determining the X-ray crystal structure of the Q425 Fab fragment separately in the presence of 
10 mM Ba2+, 10 mM Ca2+, and 10 mM EDTA, researchers concluded that one Ca2+ binds to a site 
at the interface between the light and heavy chains employing amino acid side chains from CDR-
H3 and CDR-L2 and -L3 (Zhou et al. 2005).  This site, which was also able to accommodate 
binding of the significantly larger Ba2+ ion, is completely different than what we observed in the 
LT1009:Ca2+:S1P complex structure, where two Ca2+ are coordinated by four Asp residues from 
light chain CDR-L1 and -L3 and the phosphate group on the S1P antigen (Wojciak et al. 2009). 
 
36 
 
Figure II.1 X-ray crystal structure of the LT1009 anti-sphingosine-1-phosphate antibody Fab fragment in complex 
with Ca2+.  (a) The complete LT1009 Fab fragment is depicted in ribbon diagram representation with the light chain 
in gold and the heavy chain in brown.  Two Ca2+ ions are represented as light grey spheres with the side chains that 
partially coordinate them shown as sticks.  Individual immunoglobulin domains are labeled as are the N- and C-
termini of the heavy and light chains.  (b) A close-up view of the Ca2+ binding in LT1009.  Side chains from CDR-
L1 and CDR-L3 that coordinate Ca2+ are depicted as sticks and labeled and two water molecules that are within 
generous hydrogen bonding distance of the Ca2+ ions are depicted as red spheres.  (c) An FO-FC difference electron 
density omit map built with phases from the apo LT1009 molecular replacement probe after rigid-body refinement 
and contoured at 3.5 sigma (see text) is shown in green and reveals two strong peaks at sites of the bound Ca2+ ions.  
(d) A schematic diagram of Ca2+ ion coordination by LT1009 with bond lengths in Å and light chain amino acids 
labeled.  (e) For comparison, a similar schematic diagram of Ca2+ coordination taken from the LT1009:S1P complex 
X-ray crystal structure is shown. 
 
Following closely the approach employed in the Q425 structural study, we prepared 
crystals of the LT1009 humanized anti-S1P antibody Fab fragment in 10 mM Ca2+ and collected 
a complete set of X-ray diffraction data.  Experimental estimates of phase were provided by 
molecular replacement with a search model consisting of atomic coordinates for LT1009 from 
the Fab:Ca2+:S1P complex crystal structure (PDB ID 3I9G) with S1P antigen and all nonbonded 
atoms (water, ions) removed.  After rigid-body and restrained refinement of the model against 
diffraction data to 3.0 Å resolution, FO-FC difference Fourier maps were calculated and analyzed 
for the presence of unaccounted for peaks of electron density.  Two spheres of positive electron 
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density were visible at the CDR-L1/CDR-L3 binding sites at contour level of 4.0 σ (Figure 
II.1c).  These corresponded in position almost exactly to the sites of the two Ca2+ observed in the 
antigen bound LT1009 Fab complex X-ray crystal structure.  Importantly, no significant peak 
was observed at the interface between LT1009 Fab heavy and light chain variable domains, 
strongly suggesting that, at 10 mM concentration, Ca2+ is found at the same sites as was observed 
in the antigen-bound anti-S1P complex crystal structure and not in the site proposed by 
crystallographic analysis of antibody Q425.  The significance of this observation is that the light 
chains of Q425 and LT1009 are highly similar with CDR loop sequences that differ at only four 
positions and preservation of all four Ca2+-coordinating Asp residues. 
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Table II.1 X-ray crystallography data collection and refinement statistics. 
 LT1009 Fab:Ca2+ complex 
Data collection  
X-ray source ALS 4.2.2 
Wavelength (Å) 1.0000 
Space Group I222 
Unit cell (Å)  
a 87.80 
b 114.41 
c 133.70 
Molecules/asymm. unit 1 
Resolution Range (Å)1 50.0-2.55 (2.59-2.55) 
Rsym (%) 8.7 (77.0) 
Observations 161,860 
Unique reflections 22,135 
Completeness (%) 100.0 (100.0) 
Redundancy 7.3 (5.8) 
<I/σ> 23.6 (2.3) 
Refinement  
Number of reflections 22,124 
Rwork (%) 20.9 (35.3) 
Rfree2 26.0 (46.4) 
Protein Atoms 3,365 
Ca2+/H2O/SO42- atoms 42 
Geometry (R.m.s.d.)  
Bond lengths (Å) 0.012 
Bond angles (°) 1.142 
Ramachandran plot3  
Favored 93.6 
Allowed 6.2 
Disallowed 0.2 
MolProbity score4 1.81 
PDB accession code 6VRT 
1Data in parentheses are for highest resolution shell. 
2Calculated against a cross-validation set of 5.1% of  
data selected at random prior to refinement. 
3Calculated by MolProbity (Chen et al., 2010). 
4Combines clashscore, rotamer, and Ramachandran 
evaluations to a single score, normalized to the same  
scale as X-ray resolution (Chen et al., 2010). 
 
We continued with model building and refinement against all data to a resolution limit of 
2.56 Å, ultimately yielding a model for LT1009 Fab in complex with Ca2+ with working R-factor 
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(Rwork) of 20.9% and Rfree of 26.0% and with very good stereochemistry (Table II.1).  The 
crystallographic model, which consists of heavy chain amino acids 1-217, light chain amino 
acids 1-214, two Ca2+, 28 waters, and one sulfate ion, reveals the familiar and expected Fab 
fragment immunoglobulin domain organization (Figure II.1a).  The antigen-free and -bound Fab 
models are practically identical with a root-mean squared deviation (rmsd) of 0.630 Å for Cα 
positions upon superposition.  The elbow angles, a measure for relative displacement of the 
variable and constant domains upon antigen binding, are also in close agreement with the elbow 
angle for the Fab:Ca2+:S1P complex structure at 167.5° and that of the antigen-free Fab:Ca2+ 
complex measuring 170.1° (Stanfield et al. 2006). Where the two crystallographic models differ 
is with respect to the average distance in the bonds to the two Ca2+ ions.  The interionic distance 
of 3.64 Å in the antigen-free model compares well with that of the antigen-bound complex, 
where the refined distance between the bound Ca2+ ions is 3.81 Å (Figure II.1d,e).  This suggests 
that the cationic charges are effectively shielded from one another upon antibody binding.  
However, each of the six bonds between Asp side chain oxygen atoms and Ca2+ as well as to two 
ordered water molecules are longer than the corresponding bonds in the antigen-bound complex.  
Although the magnitude of these differences is less than the estimated coordinate error as 
calculated by maximum-likelihood methods, which for the antigen-free model is 0.51 Å, the 
resulting longer bond distances agree well with established Ca—O bond distances while the 
significantly shorter Ca—O bonds observed in the 1.9 Å resolution antigen-bound complex 
approach the limits for what has been observed (Gagné and Hawthorne 2016). Therefore, our 
crystallographic analyses suggest that at 10 mM Ca2+ concentration and in the absence of S1P 
antigen, two Ca2+ bind to the anti-S1P antibody through association with the four Asp side chains 
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from CDR-L1 and -L3 and that binding of the phosphate head group of S1P is accompanied by 
Ca—O bond shortening that likely correlates with significant increased Ca2+ binding affinity. 
3.2. Detection of Ca2+ binding by LT1002 in solution 
Having established by X-ray crystallography that the anti-S1P antibody binds two Ca2+ at 
the same sites as was previously observed in the LT1009 Fab:Ca2+:S1P complex crystal 
structure, we next wished to establish methods for assessing Ca2+ binding in solution.  To this 
end, we employed equilibrium dialysis of whole murine LT1002 anti-S1P IgG1 antibody and 
detection by flame atomic absorption spectroscopy (FAAS).  By this approach, buffered 
solutions of LT1002 anti-S1P antibody that had been rendered metal ion-free by pretreatment 
with EDTA were incubated in solution containing Ca2+ and dialyzed against excess amounts of 
Ca2+-free buffer.  In order to monitor the rate of dialysis under the conditions tested, we first 
carried out an experiment in which the amount of Ca2+ retained within the dialysate fraction was 
monitored over time relative to similarly prepared and buffered whole LT3015, an antibody 
specific for lysophosphatidic acid (LPA) that we had previously demonstrated does not involve 
Ca2+ in binding to its lipid antigen (Fleming et al. 2011). By this approach, LT1002 anti-S1P 
antibody-dependent retention of Ca2+ could be detected relative to LT3015 anti-LPA antibody by 
FAAS after 24 hours and the amount of Ca2+ remaining within the dialyzed antibody samples did 
not change significantly during the final 15 hours of dialysis (Figure II.2). 
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Figure II.2  The rate of decrease in Ca2+ concentration versus time by as monitored by FAAS after equilibrium dialysis.  The 
Ca2+ concentrations (reported in reciprocal units to aid in visualization) remaining in solutions of 10 mM CaCl2 and either 0.25 
mg/mL LT1002 anti-S1P antibody (dashed line) or control LT3105 anti-LPA antibody (solid line) were measured via FAAS at 0, 
1.5, 3.5, 7.5, and 22.5 hours of dialysis against excess buffer. 
 
 
We next performed an experiment in which the concentration of Ca2+ remaining after 
dialysis was measured by FAAS and comparison was made between samples containing 10 mM 
CaCl2 in 20 mM Na-HEPES pH 7.2 buffer without antibody, 10 mM CaCl2 in buffer with 0.9 
mg/mL LT3015, 0.9 mg/mL LT1002 in buffer without Ca2+, and 10 mM CaCl2 in buffer with 0.9 
mg/mL LT1002 (Figure II.3).  After 24 hours, the samples containing LT1002 and 10 mM CaCl2 
were observed to contain significantly higher amounts of calcium on average.  These 
experiments strongly suggest that the anti-S1P antibody is capable of binding Ca2+ in solution 
independent of its antigen. 
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Figure II.3 Comparison of Ca2+ concentration measured by FAAS after 24 hours dialysis of 10 mM Ca2+ in the 
absence of antibody, in the presence of 0.9 mg/mL LT3015 anti-LPA antibody, and in the presence of 0.9 
mg/mL LT1002 anti-S1P antibody. 
3.3. Metal ion binding specificity of LT1002 
We next wished to determine whether metal ions other than Ca2+ are bound efficiently by 
LT1002 in solution.  For this experiment, we again employed replicate measurements of metal 
ions in solution after equilibrium dialysis in the presence of buffer alone, with LT1002 anti-S1P 
antibody, or in the presence of control LT3015 anti-LPA antibody.  In order to both improve the 
sensitivity and accuracy of our metal ion detection as well as expand the repertoire of metals we 
could test, we employed inductively coupled plasma-mass spectrometry (ICP-MS) detection. 
As observed previously in the FAAS experiments, LT1002 retains Ca2+ to a significantly greater 
degree than the control LT3015 antibody (Figure II.4).  Interestingly, we also observe by this 
approach that LT1002 can bind to Mg2+, though to a significantly lower extent than it binds to 
Ca2+.  It bears mentioning that the original LT1009 anti-S1P antibody Fab:Ca2+:S1P complex 
crystal was grown in 100 mM MgSO4 and that it was initially assumed that the bridging metals 
in the X-ray crystal structure must be Mg2+ before crystallographic model refinement suggested 
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otherwise.  The presence of Ca2+ in the complexes was then confirmed by ICP spectroscopy 
(Wojciak et al. 2009).  Taken together these observations suggest that the anti-S1P antibody 
binds appreciably to Mg2+ in solution though it displays a preference for Ca2+ when binding to its 
S1P antigen.  This is likely a consequence of the difference in ionic radius of Mg2+ and Ca2+ and 
the constraints of coordinating carboxylate groups of three vicinal aspartic acid residues in CDR-
L1. 
Interestingly, we observe a slight, but significant, increased binding of Ba2+ by LT1002 
relative to LT3015 control antibody.  As mentioned previously, the Ca2+-dependent anti-CD4 
antibody Q425 was observed by X-ray crystallography to bind Ba2+ at a distinct site at the 
interface between its variable heavy and light domains.  This same site was also observed to 
house one Ca2+ when the Q425 Fab fragment was crystallized in 10 mM CaCl2, though the 
coordination geometry, bond lengths, and ligand atoms are nonideal (Zhou et al. 2005).  It is 
possible that Ba2+ could bind in a similar manner in LT1002. 
We did not observe significant binding to Sr2+.  Similarly, we do not observe binding by 
LT1002 anti-S1P antibody to any of the transition metal ions tested including Zn2+, Cd2+, Mn2+, 
Co2+, and Ni2+.  Several of these ions require rather specific ligand atom types and bonding 
geometries, whereas Ca2+ has been shown to be capable of adapting to a much broader range of 
coordination spheres (Katz et al. 1996).  Finally, in single experiments we failed to observe any 
evidence of LT1002 binding with lanthanide metal ions Yb3+, Gd3+, or Eu3+ (data not shown). 
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Figure II.4 Average metal ion concentrations after 24 hours of dialysis in the presence of Na-HEPES buffer 
alone (grey), LT1002 anti-S1P antibody (white), or control LT3015 anti-LPA antibody.  Triplicate samples 
were analyzed by ICP-MS. 
 
3.4. Isothermal titration calorimetry of Ca2+ binding to LT1002 
In order to thermodynamically characterize the interaction of Ca2+ and the anti-S1P 
antibody in solution, we next carried out isothermal titration calorimetry (ITC).  By this 
approach, controlled amounts of Ca2+ were introduced to a HEPES buffered solution of LT1002 
antibody and the change in electrical current required to maintain a steady solution temperature 
is carefully measured.  This allows for direct determination of the enthalpy associated with 
binding.  Analysis of the titration endpoint can be fit to determine binding association constants, 
though which enthalpic components of the binding free energy can be deduced.  Through this 
method, full thermodynamic profiles of metals for proteins, including binding affinities, have 
been determined (Grossoehme, Spuches, and Wilcox 2010; Wilcox 2008). 
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Figure II.5 Isothermal titration calorimetry (ITC) analysis of Ca2+ binding by the LT1002 anti-S1P antibody.  
Binding isotherms were measured as CaCl2 was titrated into a Na-HEPES buffered solution containing 
LT1002.  The data fit to a model in which slightly more than 2 ions bind per site with an equilibrium 
dissociation constant (KD) of 177 μM. 
 
ITC measurements on the LT1002 antibody interaction with Ca2+ immediately revealed 
that binding of the metal is an endothermic (heat requiring) process (Figure II.5).  This is 
interesting as it implies that the driving force behind assembly of the observed antibody:metal 
complex is an increase in entropy (disorder) in the complex relative to the free protein and ions 
in solution.  The increased disorder that accompanies complex formation is almost certainly a 
consequence of freeing waters from the hydration sphere of Ca2+ upon binding to LT1002.  
Indeed, a similar dependence upon increased entropy is observed when Ca2+ is bound by EDTA 
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in Na-HEPES buffered solution, though the binding affinity is several orders of magnitude 
tighter for EDTA:Ca2+ than we measured for LT1002:Ca2+ complex formation (Ràfols et al. 
2016). 
The titration data were fit starting from a model of two ions per binding event and refined 
to roughly 2.3 ions binding with an average equilibrium binding affinity of 171 μM (KD).  This 
represents a relatively low affinity interaction.  However, when one considers the energy 
associated with shielding the charges on the two Ca2+ as they bind within close proximity of one 
another as well as the fact that only three coordination sites on each of the two bound ions are 
filled by the carboxylate oxygens of the critical four Asp residues, it seems reasonable that the 
binding affinity would not be too strong.  The measured value is certainly consistent with our 
observation that at 10 mM CaCl2, there appears to be full occupancy of Ca2+ bound throughout 
the crystal.  From the perspective of physiological relevance, 171 μM is roughly an order of 
magnitude lower than the typical plasma concentration of Ca2+.  This suggests that under 
physiological conditions, the anti-S1P antibody exists in it predominantly Ca2+-bound state.  As 
indicated from our previous antigen binding and X-ray crystallographic studies, subsequent 
binding to S1P antigen significantly increases the Ca2+ binding affinity.  Titration of Ca2+ into 
buffered LT3015 anti-LPA antibody or HEPES buffer alone revealed no interaction between 
Ca2+ and HEPES or the control antibody.  Finally, measurement LT1002:Ca2+ binding was 
performed three times with similar results. 
3.5. Sequence conservation of LT1002 Ca2+-coordinating residues in other antibodies 
Upon confirming that LT1002 binds Ca2+ in solution and having previously identified the 
specific amino acid residues responsible for Ca2+ binding, we next sought to determine what 
47 
previously characterized antibodies might also contain these residues.  To this end, we performed 
a search through the abYsis database for antibodies with three neighboring Asp residues 
(corresponding to Asp30-Asp31-Asp32) in CDR-L1 a fourth Asp residue equivalent to Asp92 in 
CDR-L3 (Swindells et al. 2017). Among the antibodies that fit this profile is the murine Q425 
anti-CD4 antibody that has been described previously (Table II.2).  Q425 was shown by surface 
plasmon resonance (SPR) spectroscopy to bind to its CD4 antigen with 85 μM affinity (KD) in 
the absence of Ca2+ and 1.6 nM affinity in the presence of 25 mM Ca2+, clearly identifying it as a 
bona fide metalloantibody (Zhou et al. 2005). It is worth noting that when the researchers 
employed SPR to assess the affinity of Ca2+ for Q425 indirectly, they arrived at a value of 187 
μM, which agrees surprisingly well with what we measured by ITC for Ca2+ binding to LT1002.  
This is despite the fact that X-ray crystallography of the Q425 Fab fragment in 10 mM CaCl2 
suggests that only one Ca2+ binds to Q425 at a site that differs completely from what is observed 
in the anti-S1P antibody crystal structures (Zhou et al. 2005). 
Table II.2 Conservation of LT1002 metal-contacting residues (bold) in CDR-L1 and -L3 
Antibody CDR-L1 CDR-L2 CDR-L3 Organism Antigen Metal 
LT1002 ITTTDIDDDMN EGNILRP LQSDNLPFT Mouse S1P Ca2+ 
Q425 ITSTDIDDDMN EGNTLRP LQSDTLPLT Mouse CD4 Ca2+/Ba2+ 
2C10 ITNTDIDDDMN EGNTLRP LQSDNMPLT Mouse dsDNA  
EGFRvIII ITSTDIDDDMN EGNTLRP LQSDNLPLF Mouse EGFR  
Gene CDR-L1 CDR-L2 CDR-L3 Organism   
Igkv17-121 ITSTDIDDDMN EGNTLRP LQSDNLP.. Mouse   
Igkv17-127 ITSTDIDDDMN EGNTLRP LQSDNMP.. Mouse   
Igkv17-1341 THNTDIDDEMH EGNTLHP LQSGNMP.. Mouse   
Igkv5-2 KASQDIDDDMN EATTLVP LQHDNFP.. Human   
Igkv17S1 KTSTDIDDDMN EGNTLRP QQSDNVP.. Rat   
Vk5.4 RAGQDIDDDMN DATTLVS LQHDNFP.. Macaque   
1Igkv17-134 is a pseudogene 
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A second antibody identified by virtue of its close homology to LT1002 that includes 
each of the four Ca2+-coordinating Asp residues is murine 2C10, which was originally identified 
as an anti-double-stranded DNA (anti-dsDNA) antibody expressed in an MRL/1 mouse model of 
the autoimmune disease systemic lupus erythematosus (SLE) (Kubota, Akatsuka, and Kanai 
1986).  Subsequent studies on 2C10 have identified its preference for DNA containing dA:dT 
base pairs over dC:dG and enhancement of DNA oxidative cleavage (Kubota et al. 1996). 
Recently, it was shown that 2C10:dsDNA complexes can enter live monocytes in culture and 
promote the expression of cytokines associated with SLE (Inoue, Ishizawa, and Kubota 2020). 
No direct evidence for the involvement of divalent metal cations has ever been reported for 
2C10, though the potential for metal-mediated coordination to phosphodiesters of the DNA 
backbone is an intriguing possibility. 
A third antibody that shares all of the LT1002 Ca2+-coordinating amino acid residues is 
the MR1 antibody that binds to a polypeptide epitope near N-terminus of a mutant epidermal 
growth factor receptor (EGFRvIII). X-ray crystallography of the complex between an MR1 
single chain variable domain (scFv) and a 13-mer antigen peptide reveal that none of the CDR-
L1 amino acids are involved in antigen binding and that no metal ions are observed or suspected 
in the complex (Landry et al. 2001). The CDR-L1 loop of the MR1 scFv adopts a conformation 
that is extremely similar to that observed in the anti-S1P and Q425 X-ray crystal structures and 
neither it nor CDR-L3 contact antigen directly.  Therefore, it is possible that metal binding by the 
MR1 light chain might serve to enhance the interaction with an even larger epitope.  However, a 
simpler alternative explanation is that antibodies bearing amino acids with Ca2+-binding potential 
do not necessarily require metals for antigen recognition and binding. 
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3.6. LT1002 Ca2+-coordinating residues are encoded in diverse light chain germline 
sequences 
One of the fundamental questions that arose in response to our observation of the critical 
role played by Ca2+ in antigen binding by LT1002 regards the manner by which the anti-S1P 
antibody developed its ability to bind Ca2. Individual antibodies arise in developing B 
lymphocytes through a series of well characterized yet complicated molecular biological 
reactions that include somatic hypermutation and recombination of naïve germline-encoded 
starting sequences throughout the processes of B cell receptor (BCR) gene assembly and 
antibody affinity maturation (Li et al. 2004). We wished to determine whether the potential for 
Ca2+ binding developed during these processes or if it can be found encoded within the germline 
DNA sequences of antibody light chain genes.  Lacking access to the cells in which the anti-S1P 
antibody originally developed, we relied upon analysis by the IgBlast server to identify the likely 
murine variable and joining genes from which LT1002 is derived (Ye et al. 2013). This returned 
the variable kappa light chain gene Igkv17-121 as an 96.8 % likely source for the LT1002 light 
chain variable domain (Martinez-Jean, Folch, and Lefranc 2001). Analysis of Igkv17-121 reveals 
that only nine base mutations differ between what is encoded by the gene and the LT1002 light 
chain.  Of these, five missense mutations alter the identities of amino acids:  Ser26 encoded for 
by the germline sequence changes to Thr in LT1002, Tyr36 becomes Phe, Lys45 is altered to 
Asn, Thr53 changes to Ile, and Val72 becomes Leu.  Notably, the four critical Ca2+-coordinating 
residues, Asp30, Asp31, Asp32, and Asp92, are present in the naïve germline variable gene 
sequence (Table II.2).  IgBlast identifies Igkj4 as the source for the light chain joining (J) gene.  
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The heavy chain was identified as derived from in frame junction of Ighv1-78 (V), Ighd1-1 (D), 
and Ighj2 (J). 
Even more intriguingly, the mouse immunoglobulin kappa gene cluster contains a 
second, highly conserved variable domain sequence, Igkv17-127, that also encodes for the four 
Ca2+-coordinating Asp residues of LT1002 (Brekke and Garrard 2004). Additionally, the 
unexpressed variable light chain pseudogene Igkv17-134 bears close homology to the consensus 
Ca2+-binding motifs (Table II.2).  The observation that the Ca2+-coordinating Asp residues are 
encoded within the germline sequences of two murine variable light chain genes inspired us to 
seek out similar patterns within other mammalian genomes.  Database searches revealed 
individual genes in each of rat (Igkv17S1), macaque (Vk5.4), and human (Igkv5-2) genomes that 
bear each of the four Asp residues in positions that correspond to murine LT1002 (Table II.2).  
Tellingly, the translated amino acid sequences flanking the four Asp residues as well as in CDR-
L2 are also highly conserved indicating that these residues play important roles and strongly 
suggesting that this germline sequence encoding for antibody CDR loops that we have observed 
to involve bridging metal ions in antibody binding is evolutionarily conserved across diverse 
mammalian genomes. 
3.7. The germline-encoded “precursor” to LT1002 binds Ca2+ 
In order to test the hypothesis that binding to Ca2+ is preserved within germline sequences 
of antibody light chain genes across diverse mammalian species, we expressed and purified 
recombinant Fab fragments of the naïve germline-encoded light and heavy chain gene precursors 
to the murine LT1002 anti-S1P antibody (Figure II.6).  Using the approach developed by Furuta, 
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et al., we engineered recombinant baculovirus containing the germline-encoded naïve sequences 
for LT1002 light and heavy chains with N-terminal Gp64 signal peptides on each chain and a C-
terminal hexa-histidine tag on the heavy chain (Furuta et al. 2010). Our version of the Igkv17-
121 light chain gene contained an in frame Igkj4 and constant light chain.  Expression of the 
antibody in Sf9 insect cell suspensions and Western blot detection with an anti-His antibody 
revealed that significant amounts of the heavy chain were secreted into media and that the size of 
the heavy chain band correlated to intact, covalently Cys-linked Fab under nonreducing 
conditions. After optimizing virus titer for optimal expression yield, antibody Fab fragments 
were purified to homogeneity via nickel affinity and size exclusion chromatography (Figure 
II.6). 
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Figure II.6 Expression and purification of LT1002 germline-encoded precursor Fab fragment from Sf9 insect 
cell suspension cultures.  (a) pFastBac Dual plasmid with both heavy and light chain inserted and polyhedrin 
promoter for the heavy chain and p10 promoter for the light chain was designed. Signal peptide gp64 was used 
to secret the antibody. (b) Anti-His Western blot detection of secreted metalloantibody precursor Fab fragment 
from P1 baculovirus-infected Sf9 cells. 1,2, and 3 secreted Fab antibodies, 4. negative control (cells with no 
virus), 5. negative control (intact virus), 6. IKK (Intracellular protein control), 7, 8, and 9 intracellular Fab 
antibodies, 10, 11, and 12 negative control, 13,14, and 15 secreted non-reduced Fab antibodies. (c) Coomassie-
stained 15% SDS PAGE gel for samples from Ni column purification. The size of Fab antibody is 24kD, and 
the E2-E4 elutes contain most of the proteins were combined. The double bands show heavy and light chain of 
the antibody. (d) Size exclusion chromatography using Superdex 75 16/60 of the His-tagged Fab antibody. (e) 
Coomassie-stained 15% SDS PAGE gel indicating the fractions from SEC column purification. 
 
The purified naïve germline antibody Fab was tested for its ability to bind Ca2+ by 
equilibrium dialysis and ICP-MS.  For this experiment, solutions of Na-HEPES buffer at pH 7.2 
with and without the addition of 10 mM CaCl2 were used as controls to establish the detection 
range of the ICP-MS instrument (Figure II.7).  After extensive dialysis of the buffered 10 mM 
CaCl2 solution, there was almost no Ca2+ detected.  Incubation of 10 mM CaCl2 in the presence 
of the germline-encoded Fab fragment, however, resulted in retention of a significantly increased 
53 
amount of Ca2+.  Measurably significant levels of Ca2+ were detected after dialysis in the 
presence of control LT3015 anti-LPA antibody, but these were only slightly higher than for the 
buffer control.  We conclude that the CDR amino acid sequences encoded for by the light chain 
of murine kappa light chain gene Igkv17-121 and conserved across genomes of diverse 
mammals harbor inherent Ca2+ binding potential. 
 
Figure II.7 ICP-MS detection of Ca2+ from aqueous samples.  “HEPES” and “HEPES 10 mM Ca2+” are 
samples that were not subjected to dialysis and represent the low and high levels of Ca2+, respectively, used in 
the solutions during this experiment.  Samples labeled “Dialyzed” are measured after dialysis against excess 
Na-HEPES pH 7.2 buffer. 
4. Discussion 
The incorporation of metals as interfacial bridging factors greatly expands the potential of 
proteins for folding stability, catalysis, and selective binding to molecular targets.  Although 
numerous metalloproteins have been identified and characterized, the involvement of interfacial 
metals in antigen recognition by proteins of the adaptive immune system has remained somewhat 
dubious.  Where there is clear evidence for the involvement of metals in antigen binding, as in 
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the case of CD4 binding by the murine Q425 antibody, it is unclear exactly how Ca2+ binding 
promotes the observed significant enhancement of antigen binding and resultant disruption of 
HIV infection (Zhou et al. 2005).  Another instance of suspected involvement of bridging metal 
ions in immunocomplex formation involves the human T Cell Receptor (TCR) ANi2.3 that is 
associated with Ni2+-contact hypersensitivity (Vollmer et al. 1997; Lu et al. 2003).  Previous 
structural and biochemical characterization of a complex between TCR ANi2.3 and MHCII 
protein DR52c bearing a peptide that was identified by in vitro selection to bind with high 
affinity and activate the ANi2.3 T cell reveals that the ε-amino group from a particular Lys 
residue on the peptide antigen interacts with TCR residues that likely provide a binding site for a 
bridging Ni2+ (Yin et al. 2012).  However, direct observation of the bound Ni2+ has not been 
reported.  Our structural and biochemical analyses of the murine LT1002 anti-S1P antibody and 
its humanized form, LT1009, provide a definitive case for the involvement of Ca2+ as a bridging 
factor to aid in selective binding to a target antigen. 
Our X-ray crystallographic data strongly suggest that at 10 mM Ca2+ concentration and in 
the absence of S1P antigen, two Ca2+ bind at the same site as was observed in the antigen-bound 
complex.  The two Ca2+ directly contact Asp30, Asp31, and Asp32 from CDR-L1 as well as 
Asp92 from CDR-L3 through coordinate bonds that are within the expected range for Ca—O 
(Gagne and Hawthorne 2016).  This arrangement leaves three sites available (assuming 
octahedral coordination) for each bound Ca2+ that can be used to bind antigens.  It bears 
mentioning that this portion of the anti-S1P antibody is exposed to solvent within the crystal and 
that no atoms from neighboring complexes are involved in stabilizing the two bound Ca2+.  We 
conclude that this is the preferred mode for Ca2+ binding to the anti-S1P antibody and that the 
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presence of antigen, while stabilizing the interaction and shortening the distances between 
bonded atoms, does not significantly alter the Ca2+ binding site.  This is an important conclusion 
as comparison with the antigen-free Q425:Ca2+ complex X-ray crystal structure reveals an 
alternative Ca2+ binding site (Zhou et al. 2005). This is despite the fact that the Q425 and 
LT1002 antibody display 94.7% sequence identity through within their variable domains 
including sharing all of the LT1002 Ca2+-coordinating residues.  In the absence of more detailed 
study, it is impossible to know for certain how Q425 employs Ca2+ to bind to its CD4 antigen.  
Nonetheless, at present it appears that antibody kappa light chains derived from the murine Igkv-
17 might be capable of employing multiple modes of metal binding in order to recognize and 
bind to diverse antigens. 
Our characterization of ion binding by LT1002 in solution reveals that Ca2+ is preferred, 
though Mg2+ can also associate with the anti-S1P antibody.  Ca2+ and Mg2+ bind to similar sites 
on proteins although, due primarily to the greater ionic radius of Ca2+ and consequent exclusive 
requirement for monodentate ligand binding, with differing consequences.  In several notable 
cases, Ca2+ binding impedes catalysis by metalloenzymes where the smaller Mg2+ co-factor 
favors it (Mordasini, Curioni, and Andreoni 2003; Peeraer et al. 2004).  ITC revealed a relatively 
low Ca2+ binding affinity for LT1002 with a measured dissociate constant (KD) for binding to 
two Ca2+ at 171 μM.  This is significant on several counts.  First, this is roughly ten times lower 
than the typical concentration of Ca2+ in blood plasma, which suggests that LT1002 is generally 
preloaded with Ca2+ as it circulates in the blood stream.  We had previously speculated that the 
antibody might bind to Ca2+ and S1P simultaneously through a concerted binding mechanism or 
that initial antigen binding might induce subsequent affinity for Ca2+.  In light of the present 
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study, we are confident that circulating anti-S1P antibodies associate with Ca2+ independent of 
antigen.  Secondly, the low affinity correlates with the significant increase in bond distances to 
the two Ca2+ ions observed in the antigen-free X-ray crystal structure relative to its S1P antigen-
bound structure.  This suggests that the Ca2+ are bound with significantly higher affinity upon 
antigen binding and explains why Ca2+ remained bound even at 100 mM Mg2+ concentration 
used for crystallization of the S1P antigen-bound complex (Wojciak et al. 2009).  Finally, our 
measured value for Ca2+ binding agrees remarkably well with that deduced in an elegant SPR 
study on the closely related anti-CD4 Q425 antibody (Zhou et al. 2005).  
Identification of the interfacial Ca2+-coordination signature (three neighboring Asp 
residues at positions 30-32 in CDR-L1, Asp at position 92 in CDR-L3) in other antibodies 
immediately raises the question of whether implementation of bridging Ca2+ ions is a common 
mechanism employed by antibodies?  Other than Q425, neither of the other two antibodies 
identified as containing the Ca2+-coordination signature, the 2C10 anti-dsDNA antibody and the 
MR1 anti-EGFRvIII antibody, are known or suspected to rely upon bridging metal ions to bind 
their respective antigens.  By expressing the murine Igkv17-121 germline sequence as part of a 
naïve antibody Fab fragment and confirming its ability to bind Ca2+ in solution, we have proven 
that Ca2+ binding potential is inherent to these sequences and preserved within the mouse 
germline repertoire.  Our observation of antibody light chain genes that contain the Ca2+-
coordinating residues within germline sequences of diverse mammals makes a strong case for 
interfacial Ca2+-dependent antigen recognition as an evolutionarily conserved component of the 
mammalian antibody repertoire. 
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Chapter III 
X-ray crystallography of two camelid VHH 
antibodies with PcrV antigen 
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1.Introduction 
Pseudomonas aeruginosa is a gram negative bacteria that its infections can cause disease 
and death among people with weakened immune responses, such as individuals suffering from 
HIV, acute pneumonia, cancer patients, or burn victims. People with cystic fibrosis also suffer 
from Pseudomonas (Kobayashi, Kobayashi, and Kawai 2009; Trautmann, Lepper, and Haller 
2005). An important virulence factor of this bacteria shared with other gram negative bacteria is 
the type III secretion system (T3SS). T3SS is molecular needle machinery that transfers effector 
proteins directly from the bacterium cytosol into the host cell. This complex macromolecular 
machine can manipulate into the host cell in many different ways and works regulated (Galle, 
Carpentier, and Beyaert 2012). Recently, cryo-electron microscopy studies have investigated to 
find out the structure of T3SS. The virulence factors of T3SS has been a target site for many 
vaccines and therapeutics. T3SS uses a needle-like shape to transfer the effector protein into the 
host cell. T3SS assembly has different components including: a cytosolic ATPase complex, a 
cytoplasmic ring (C-ring), an inner membrane export apparatus, a basal body (which is in the 
bacterial inner and outer membranes, and encircles an inner rod and a needle), and a 
translocation pore in the host cell membrane (Figure III.1).  The tip of the complex is responsible 
for sensing the environment around the host cell, regulation of secretion, and physically bridging 
the needle into the host membrane and facilitate the translocon pore in host cell membrane (Deng 
et al. 2017).  
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Figure III.1 Simple model that overviews the key structural elements for T3SS. The inner membrane and 
bacterial cytoplasm include ATPase complex, C-ring, Chaperone and Effector protein. The periplasm includes 
the basal body and the outer membrane includes the needle shape which connects to the V-tip complex and 
translocon pore in the host cell membrane (Sato and Frank 2011).   
 
One of the unique mechanisms in T3SS is that the secreted protein does not have a 
conserved cleavable signal. Type III secreted proteins have a secreted signal and are enriched 
with serine, threonine, isoleucine and proline but have limited peptide sequence that is 
conserved. This explains why type III secretion signal can handle multiple mutations (Anderson 
1997). 
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Moreover, studies have shown that an unknown signal triggers the conformational change 
of the translocator and follows with host cell contact. This leads to the interaction between the 
translocator and the tip protein known as PcrV (Armentrout and Rietsch 2016). PcrV is an 
essential part of Pseudomonas T3SS secretion system that has the ability to infect and kill the 
host cell. By knocking down the PcrV gene, the exotoxins leak to the bacterial growth medium 
results in stopping the cytotoxicity in vivo and in vitro. Therefore, PcrV is an attractive target for 
blocking Pseudomonas infection in patients (Audia et al. 2013; Lee et al. 2010).  
Furthermore, recent studies have focused on nanobodies, which are the novel class of 
therapeutics. Nanobodies are based on immunoglobulin single variable domain. It could be 
derived from variable heavy chain only. These antibodies naturally derive from camelids. The 
benefits of using single chain heavy variable domain over the conventional antibodies is: (i) 
superior solubility, (ii) biophysically stability and (iii) easy amenability of connecting 
monovalent nanobodies with a linker sequence to form multivalent polypeptide chain 
(Coppieters et al. 2006; Jahnichen et al. 2010).  
InhibRx, LLC is a San Diego-based pharmaceutical company that has raised antibodies 
that specifically bind to PcrV. The antibodies bind to the foreign pathogen and stabilize it for 
removal by blood cells. The InhibRx scientists chose camels for their source of anti-PcrV 
antibodies. We collaborated with InhibRx to use their camelid antibodies and prepare stable 
complexes with PcrV and crystalize and determine the complex structures. Unfortunately, PcrV 
is very flexible to crystallize on its own; therefore, we suspect that this is due to the inherent 
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flexibility in PcrV. Moreover, LcrV (Protein Data Bank entry 1R6F) is PcrV homologe that has 
been crystallized before. Figure III.2 is showing PcrV homologous and their similarity.  
 
 
Figure III.2 Homologous of PcrV. It is showing V-tip protein Ysc family: PcrV, LcrV, AcrV and Vp 1659. 
There is 36.4% identity between PcrV and LcrV and 64.4% similarity (Sato and Frank 2011).  
 
Figure III.3 is showing models of V-tip protein family. Using LcrV as a template, the 
other models were made by using Discovery Studio 3.0 software. The model is showing a 
conserved coiled-coil structure of two α-helices by globular domains at each end (Sato and 
Frank 2011).  
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Figure III.3 Structural models of V-tip protein family. In all models coiled core α-helices structure is 
conserved. The  white circle on the globular domain on PcrV and LcrV is indicating the epitope protecting 
(Sato and Frank 2011).  
 
By looking at LcrV sequence, we found out that the first 24 amino acid residues of PcrV 
causes its flexibility and this is the reason it did not crystallize (Derewenda et al. 2004).  
Therefore, we removed 24 amino acid at the beginning of PcrV sequence and prepared the 
antibody:PcrV complex: PcrV:VHH15, PcrV:VHH18, PcrV:VHH15:VHH18, and 
PcrV:VHH18:VHH20. We were able to crystalize and solve the crystal structure at high (near 
atomic) resolution by X-ray crystallography. This is the first time that high resolution 
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crystallographic models of PcrV has been solved and it can help in the development of the next 
generation of therapies that target Pseudomonas aeruginosa infection.  
In order to find out that bispecific VHH antibodies can bind to PcrV and neutralize the 
pathogen, we crystallized and solved PcrV with two covalently linked camelid antibodies 
structure.  
2.Materials and Methods 
2.1 PcrV and VHH plasmid 
InhibRx, LLC has produced and supplies VHH15, VHH18 and VHH20 nanobodies with 
PcrV. The plasmid used for expression of PcrV-His tagged was pET15b and the plasmid used for 
PcrV with the nanobodies was pET21-PcrV (15,18,20)-VHH. Table III.1 describes the vector, 
plasmid name, number of amino acids, molecular weight, extinction coefficient and isoelectric 
point for PcrV and VHH nanobodies. 
Table III.1 PcrV:VHH complex plasmid and vector. 
Name Vector Plasmid name AA MW pI Ext. coeff. 
  PcrV-His  pET15b  pET15b-PcrV  314  34446.8  5.75  0.868 
  PcrV15-VHH-His  pET21  pET21-PcrV15-VHH  133  14662.4  8.64  1.642 
  PcrV20-VHH-His  pET21  pET21-PcrV20-VHH  133  14659.5  9.49  1.572 
  PcrV18-VHH-His  pET21  pET21-PcrV18-VHH  132  14574.24  9.03  1.754 
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2.2 PcrV:VHH complex preparation 
We prepared PcrV:VHH15, PcrV:VHH18, PcrV:VHH15:VHH18, and 
PcrV:VHH18:VHH20 complexes using the 1:2 ratio. We were expecting that PcrV has two 
binding sites. After preparing the complexes, I ran it on superdex 75 16/60 size exclusion column 
that was connected to ÄKTA (GE Healthcare), it has been equilibrated with SEC buffer pH 7.5 
(25 mM Tris-HCl pH 8.0, 150 mM NaCl). Fraction collector at 2 mL per fraction collected 
purified protein, and peak fractions has been combined and concentrated with 50 kDa-cutoff 
membrane concentrator (Millipore) to 10 mg/mL. Protein was flash frozen in liquid nitrogen and 
stored at -80°C. Protein concentration was determined by BioRad Protein Assay (BioRad). After 
collecting the samples from size exclusion column, I ran them on 15% SDS-PAGE gel to 
confirm the right molecular weight for the antibody: antigen complex and the nanobodies.  
2.3 Removing His-tagged PcrV using Thrombin 
 In order to further stabilize PcrV and be able to crystalize it, I removed His-tagged from 
PcrV using Biotinylated Thrombin. PcrV has a cleavable specific Thrombin cut site sequence, 
which is LeuValProArg↓GlySer that cuts between Arg and Gly. I used the Novagen Biotinylated 
Thrombin kit and I incubated PcrV with different amounts of enzyme by making a serial dilution 
of Thrombin in Thrombin storage/dilution buffer, the dilutions were from 1:25, 1:50, 1:100 and 
1:200 ratio. This dilution will contain approximately 0.04, 0.02, 0.01, and 0.005 U enzyme per 
μL. Also, I used different reaction (incubation) time at room temperature by taking 10 μL 
aliquots into 10 μL 2X SDS sample buffer after 2, 4, 8 and 16 h. Finally, I used different 
concentrations of PcrV in order to reach the optimum pure PcrV without His-tag.  
66 
2.4 PcrV: VHH15:VHH18 complex formation and co-crystallization 
One of the methods used for crystallization of protein samples is sitting drop vapor 
diffusion method. I used Crystal Nanoliter Protein Crystallization Robot (mosquito®) to set up 
the crystal trays in Swissci 96-well 2-drop MRC Crystallization Plates. Different conditions of 
crystal screen were used, such as: PEG/Ion, HR2-126, PEG/Ion 2, HR2-098, Index HR2-144, 
Crystal Screen HT, and HR2-110 are from Hampton Research. Also, I used MCSG-1, MCSG-2, 
MCSG-3, and MCSG-4 Crystal Screen from Microlytic for extensive screening. In order to grow 
better crystals, I have optimized the crystal screening solutions by using different range of pH 
(4.0-10.5), different concentrations of PEG, different concentrations of Tris buffer and etc. 
Furthermore, I have used the micro seeding technique to grow larger crystals by using micro 
crystal of PcrV complex with the antibody and mixing it with optimized reservoir solution. In 
order to monitor crystal trays, I used automated Formulatrix Rock Imager.  
Another method to grow crystals is hanging drop vapor diffusion method. For this 
method, I used 24-well plates at room temperature. Hampton research crystal screen HR2-110 
was diluted with water by 1:2 ratio. 1 μL of protein was combined with an equal amount of 
reservoir solution on the surface of a siliconized glass cover slip. The slip was sealed with high 
vacuum grease over 1 mL of reservoir solution to allow for slow equilibration. 
2.5 X-ray crystallography and structure solution and refinement 
Synchrotron data were collected on a ALS 5.0.2 detector at the Advanced Light Source 
Beamline from Berkeley National Laboratory. Indexing and scaling was carried out with 
HKL2000 (Otwinowski and Minor 1997) and subsequently converted using ScalepacktoMTZ 
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within CCP4; data collection statistics are presented in Table 2. Molecular replacement was 
performed via Phaser-MR (McCoy et al. 2007) in PHENIX using LcrV (PDB ID 1R6F) as a 
probe with ions, antigen, and solvent molecules removed. Model building was carried out in 
COOT (Emsley and Cowtan 2004). All further refinements were made in PHENIX. Analysis 
was provided by MolProbity (Davis et al. 2007).  
3.Results 
 
We were able to crystalize PcrV: VHH15:VHH20 complex and solve the crystal structure 
with 2.67 Å resolution. This was the first time that crystal structure of PcrV with two covalently 
link VHH nanobodies was solved. In order to crystalize the complex, 24 amino acids were 
removed from the N-terminus of PcrV (PcrVΔ24).  
3.1 Removing His-tag from PcrV using Thrombin  
By using Biotinylated Thrombin, I removed the His-tag from PcrV. Figure III.4 is 
showing 15% SDS-PAGE gel where His-tag of PcrVΔ24 was removed. Based on incubating 
different Thrombin dilutions and with different incubation time, I used 4 hrs incubation with 
1:200 ratio of diluted Thrombin in the dilution buffer.  
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Figure III.4 Using Thrombin to remove His-tag from PcrV shown with 15% SDS-PAGE gel. First lane is the 
molecular marker, Lane 1is Thrombin dilution 1:25 ratio, Lane 2 is 1:50 ratio, Lane 3 is 1:100 ratio and Lane 4 
is 1:200 ratio after 2 hrs. Lane 5 is the negative control. Lane 6 is Thrombin dilution 1:25 ratio, Lane 7 is 1:50 
ratio, Lane 8 is 1:100 ratio and Lane 9 is 1:200 ratio after 4 hrs.  Lane 10 is Thrombin dilution 1:25 ratio, Lane 
11 is 1:50 ratio, Lane 12 is 1:100 ratio and Lane 13 is 1:200 ratio after 8 hrs. Lane 14 is Thrombin dilution 1:25 
ratio, Lane 15 is 1:50 ratio, Lane 16 is 1:100 ratio and Lane 17 is 1:200 ratio after 16 hrs.  
3.2 PcrV: VHH15:VHH18 complex formation and purification 
Figure III.5 is indicating the complex formation of PcrV: VHH15:VHH18 using superdex 
75 16/60 size exclusion column that was connected to ÄKTA. The top figure is the overlay 
chromatograms of PcrV: VHH15, PcrV: VHH18, PcrV: VHH15:VHH18, and PcrV: 
VHH18:VHH20 complexes. The peak that was eluted at 50 mL is the complex and the peaks that 
elute at 80-90 mL are the excess VHH antibody. Among all complexes, we were able to 
crystalize PcrV: VHH15:VHH18 complex. The bottom figure shows the complexes prepared 
from ÄKTA on 15% SDS-PAGE gel. The molecular weight of VHH and the PcrV are 
approximately 15 kDa and 30 kDa, respectively.  
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Figure III.5 PcrV:VHH15:VHH18 complex formation and purification. Top part is chromatograms monitoring the 
absorbance of protein complexes as they elute from a size exclusion column. The major peaks in each of the four 
runs are the PcrV: Antibody complexes indicated. Excess antibody peaks elute between 80-90 mL. The bottom part 
is coomassie-stained 15% SDS-PAGE gel showing the PcrV: Antibody complexes before (lanes 1- 4) and after 
(lanes 5-8) size exclusion chromatography. Lane 9 shows excess VHH18 and VHH20 antibodies, and lane 10 is a 
molecular weight standard.  
3.3 Crystal screening of PcrV: VHH15:VHH18 complex  
In order to grow crystals, I used different crystal screening solutions. By using sitting 
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drop diffusion method with mosquito robot, we first got microcrystals by using 2.0M sodium 
formate, 0.1M Bis-Tris propane pH 7.0; 0.1M Na2HPO4/KH2PO4 pH 6.2; 25 % (v/v) 1,2-
propanediol, 10 % (v/v) glycerol screen solution. Also, we got needle cluster by using 10% PEG 
8K; 10% EG; 0.1M HEPES screen solution. Then, we got hexagonal plate by using 1.5M 
ammonium chloride; 0.1M Bis-Tris propane pH 7.0; 0.1M imidazole: HCl, pH 8; 1M ammonium 
phosphate dibasic screen solution (Figure III.6A). Figure III.6B is showing larger crystals that 
grow over time by crystallization by hand using hanging drop diffusion method. 
 
Figure III.6 Crystal figures for PcrV: VHH15:VHH18 complex (A) Photographs of microcrystals, needle 
clusters and hexagonal plates setting up by robot. The dotted red circles are showing the hexagonal plates. (B) 
Photographs of initial crystals of PcrV: VHH18:VHH20 (left) and PcrV: VHH18:VHH20 (right) complexes. 
The black bar is 100 μm.  
3.4 Collection of the X-ray Diffraction  
After crystallization of the complex, we have stored the crystals in optimum cryo 
solutions to avoid icing on the crystals. The crystals were shipped to Berkeley National 
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Laboratory. Synchrotron data were collected on ALS 5.0.2 detector at the Advanced Light 
Source Beamline. The crystal was mounted in front of the X-ray beam and the diffraction pattern 
of crystal was collected at different angles (Figure III.7). Complete X-ray diffraction data were 
collected at 2.67 Å resolution. 
 
Figure III.7 Diffraction of protein crystal PcrV:VHH15:VHH18 in front of X-ray beam.  
 
3.5 Table and refinement statistics 
        After collecting the diffraction pattern we used molecular replacement that was 
performed via Phaser-MR (McCoy et al. 2007) in PHENIX using LcrV (PDB ID 1R6F) as 
a probe with ions, antigen, and solvent molecules removed. Model building was carried out 
in COOT (Emsley and Cowtan 2004). All further refinements were made in PHENIX. 
Analysis was provided by MolProbity (Davis et al. 2007). The crystal was determined to be 
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made up of cubic unit cells with the space group P32. The dimension of the unit cell is 
a=106.56Å, b=106.56Å, c=126.45Å, and α=90°, β=90°, γ=120°.  
 Table III.2 X-ray crystallography data collection and refinement statistics. 
Title 1 Title 2Title 3 
 PcrV:VHH15:VHH18 
Data collection  
X-ray source ALS 5.0.2 
Wavelength (Å) 1.0000 
Space Group P32 
Unit cell (Å)  
a, b, c (Å) 106.56, 106.56, 126.45 
α, β, γ (°) 90, 90, 120 
Resolution Range (Å)1 126.44-2.67 (2.80-2.67) 
Rsym (%) 14.9 (76.9) 
Observations 229,021 
Unique reflections 24,086 
Completeness (%) 100.0 (100.0) 
Redundancy 9.5 (9.6) 
Average intensity (<I/σ>) 8.0 (1.8) 
Refinement  
Number of reflections 22,799 
Rcryst (%) 19.3 (31.5) 
Rfree2 26.8 (44.0) 
Protein Atoms 4,055 
Water- Atoms 107 
R.m.s.d.  
Bond lengths (Å) 0.014 
Bond angles (°) 1.673 
Mean B (Å2) 86.57 
  
Ramachandran plot3  
Favored 92.0 
Allowed 6.2 
Disallowed 1.8 
MolProbity score4 2.39 
PDB accession code N/A 
 
3.6 X-ray crystal structure of PcrV: VHH15:VHH18 complex 
X-ray crystal structure of PcrV: VHH15:VHH18 complex indicates that the complex by 
itself is monomer but in the unit cell forms a trimer. Each VHH antibody at both ends of PcrV is 
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twisting with a 3- fold rotational symmetry. Figure III.8 shows the X-ray crystal structure of 
PcrV with VHH15 and VHH18.  
 
Figure III.8 X-ray crystal structure of PcrV:VHH15:VHH18 complex depicted in ribbon diagram. PcrV is 
illustrated with green color VHH15 and VHH18 are illustrated in cyan and purple color respectively. PcrV is 
represented as coiled core α-helices structure and VHH15 and VHH18 nanobodies have, immunoglobulin 
domains.  Individual immunoglobulin domains VHH15 and VHH18 are presented at N- and C-termini of PcrV.   
 
4.Conclusion and future direction 
We were able to successfully get the crystal structure of PcrV with two covalently linked 
camelid nanobodies VHH15 and VHH18 for the first time. PcrV has always been an interesting 
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target for drugs. PcrV is the protein tip at the T3SS secretion system found in many gram-
negative bacteria. PcrV has an essential role, which is the interaction of the needle-shape protein 
secretion system of T3SS to the host membrane cell. Disrupting PcrV can lead to the effector 
protein leakage and T3SS not working effectively. Many scientists have tried to crystallize PcrV 
with antibodies but because PcrV is very unstable, they were not able to crystalize it. As we 
searched further in the literature, we found out that the homolog of PcrV, LcrV has been 
crystallized before. By looking at its sequence, we found out the reason that PcrV is not 
crystalizing is due to the first 24 amino acid of the protein, which makes it floppy. By removing 
the amino acids and the His-tag from PcrV, we were able to get microcrystals, but with 
optimizing the crystal screening solutions we got crystals that were about 100 μm big. Also, the 
diffraction data confirmed that our results were good.  
The crystal structure indicates that both VHH15 and VHH18 binds simultaneously to 
opposite ends of PcrV protein. Furthermore, in the crystal, PcrV forms an intertwined trimer (see 
the monomer illustration of the structure in Figure III.8). Moreover, the placement of VHH15 
and VHH18 of neighboring PcrV proteins correlates with the length of the linker in the most 
potent bivalent antibody-based antibiotic. 
For future research, I would like to suggest in vivo studies to test the efficiency and 
pharmacokinetics of camelid antibodies on Pseudomonas aeruginosa infection. Also, by looking 
at the literature, I found out that PcrV models are assembled as oligomers, possibly forming 
pentameric rings on top of P. aeruginosa T3SS needle. This model suggests multiple binding 
sites for PcrV. The potent nanobodies used for this therapy could be bivalent (combinations of 
two identical) and biparatopic (combinations of two different) nanobodies instead of monovalent 
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antibodies. By looking at our data, we found out that our crystal forms trimer in a unit cell, 
which could be consistent with the model suggesting oligomeric compound. In order to find out 
multiple binding sites on PcrV, screening biparatopic nanobodies library is necessary and we can 
test this with binding ELISA signals of nanobodies. By mutations of the binding sites, we can 
measure different antibody binding to PcrV.  
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Chapter IV  
Engineering novel selectivity into 
metalloantibodies 
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1.Introduction 
Metalloproteins have been identified either as catalytic enzymes or metals as cofactors 
for proteins, such as hemoglobin or cytochrome-c. Among many metalloproteins, Zn2+, Cu2+ and 
Fe2+ are the most active metals used in metalloprotein structure. Our metalloantibodies binds to 
Ca2+ and much less extent to Mg2+; therefore, we were interested in changing the metal binding 
to some interesting metals like zinc.  
Engineering selectivity of metalloantibodies and antibodies generation can occur with site 
directed mutagenesis and phage display method. Nowadays, human antibodies are generated in 
vitro by antibody engineering technologies, such as phage display, construction of antibody 
fragments, immunomodulatory antibodies, and cell-free systems (Edwards and He 2012).  
We were interested in using site directed mutagenesis to change the amino acid sequence 
on the CDRL1-L3 loops of the antibody. X-ray crystallography has showed us the binding 
coordinate sites of the antibody to metals. Aspartic acid 30-32 and aspartic acid 92 were the 
involved residues in the metal coordination site, therefore, we were interested to structurally 
change the amino acids that were involved in the metal coordination site (Figure IV.1). 
Moreover, by changing the residues we were expecting to change the specificity of the antibody 
to different metals. I have changed aspartic acids (D30,31,32) to cysteine (C30), histidine (H31) 
and cysteine (C32) and aspartic acid (D92) to histidine (H92). I also generated two other 
construct D3192H and D30D32C in order to change the metal binding coordination of the 
antibody from Ca2+ to Zn2+, Ni2+ and Co2+. 
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Figure IV.1 Schematic diagram of CDR loops of the light chain in coordination with Ca2+ and S1P. The bond 
lengths are shown in Å and the amino acid involved in the interaction are labeled (J. M. Wojciak et al. 2009).  
 
With these sites directed mutagenesis, we wanted to test whether D3192H interacts with 
Cu2+ or D3032C interacts with Fe2+ or Cu2+. As we searched in the literature, we found the 
protein copper complexes have the metal coordination by two histidine and a cysteine residue 
and the metal is used as a cofactor for protein. One example of that protein is amicyanin, which 
is a type I copper protein and is involved in electron transfer. In bacteria like Paracoccus 
denitrificans, amicyanin is part of the three membrane redox complex with methylamine 
dehydrogenase (MADH) and cytochrome c (Holm, Kennepohl, and Solomon 1996).  
However, metal-to-donor atom coordination and distances and angles in proteins are also 
important in the metal protein binding. In small molecule crystal structure, the target distance 
between metal and the donor atom is usually within a + 0.75 Å distance (Harding 2002).  
Moreover, looking at zinc finger motifs, one will find out that Cys2His2 like fold group is 
characterized as a zinc finger motif, which is common in mammalian transcription factor (Pabo, 
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Peisach, and Grant 2001). Engineered zinc finger motifs are applied in zinc finger transcription 
factors and zinc finger nucleases. There are other applications to zinc finger motifs that have 
been discovered (Jamieson, Miller, and Pabo 2003). In this case the metalloprotein is a catalytic 
enzyme.   
Using site directed mutagenesis, we were able to express metalloantibody that binds to 
zinc with the D3032C/D3192H construct. We have confirmed its metal binding using 
Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Microscale Thermophoresis 
(MST). In this chapter, I introduce the method that I used for mutating key residues as well as 
protein expression and purification of the mutant antibodies with the results from ICP-MS and 
MST techniques that I used.  
2.Materials and Methods 
2.1 Cloning heavy and light chain genes into pFastBac Dual plasmid 
The mouse IgG has been found from database searches of Ig germline genes, and it is 
closest to murine LT1002. The pFastBac Dual plasmid was generated by miniprep IgKV17-21 
and IgHV178 from pUC57 (GenScript) into XL1-Blue cell line and measured the concentration 
of DNA plasmid using Nanodrop. The signal peptide gp64 that working for both antibody and 
Sf9 cells were inserted in the beginning of the heavy chain for the antibody to be secreted out 
from the insect cell. 
Double digestion of the pFastBac Dual plasmid with NEB enzymes were done with 
EcoRI-HF and NheI-HF enzymes in cut smart buffer. I ran the plasmid on 1% agarose gel after 
the restriction enzymes digestion and cut the appropriate band; then, I used gel extraction kit to 
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extract the DNA. I did the same process for pUC57 plasmid by double digestion of pUC57 
plasmid light and heavy chain, then ran it on 1% agarose gel, cut the bands and used gel 
extraction kit. I did the ligation of the heavy chain with pFastBac Dual plasmid by using double 
digestion enzyme EcoRI and HindIII. For the ligation, I first used vector (1μL), inserted (0, 2, 5, 
10 μL), 10 x buffer (2 μL), ligation enzyme (1μL) and water to adjust the volume to 16μL total. 
After leaving the reaction at room temperature for 3:45 hr, I transferred the ligation mixture into 
XL1-Blue cells and did miniprep. To check if the ligation worked, I did EcoRV-HF and PstI 
digestion at 37°C for 2 hr. After cloning both heavy and light chains into pFastBac Dual plasmid, 
I transformed 1.2 μL of the plasmid into DH10Bac cells and on ice for 30 min, 45 second in 
water bath 42°C and 2 min on ice again. I added 250 μL of SOC buffer to the same tube and let it 
shake in the incubator 37°C for about 6 hrs. I prepared and used fresh x-gal plates which contains 
Kanamycin, Gentamicin, and Tetracycline antibiotics. I covered the x-gal plates with aluminum 
foil and left it at the incubator for 48 hrs. I picked 5 white colonies and 2 blue colonies for the 
negative control. After doing the miniprep, I kept the cells in ethanol and stored them at -20°C. 
2.2 Sf9 Transfection 
Sf9 cells were grown in suspension culture with at least 95% viability and then seeded 
into 6-well tissue culture plates at 1 x 106 cells in 2 mL of ESF-921 insect cell culture medium 
(Expression Systems) per well. 1 μL bacmid DNA (when the miniprep was done on the same 
day) was mixed with 100 μL ESF-921 media, and 8 μL of CellFECTINâ II Reagent (Thermo 
Scientific) diluted in 100 μL of ESF-921 media. Here is the procedure that I followed: Mix the 
two solutions together to form complex for 45-60 minutes, and then add 209 μL of the complex 
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into the well. Incubate cells for 6 hours in a 27°C incubator, and aspirate the transfection mixture 
then add 2mL ESF-921 media with 10% heat inactive and filtered FBS (HyClone) in each well to 
incubate plates for 72 hours at 27°C.  Harvest first generation (P1) of baculovirus.  P1 
baculovirus was purified from cells and debris by centrifugation at 500xG for 5 minutes and 
stored at 4°C. 
2.3 Antibody fab expression optimization in Sf9 cells 
2 x 106 cells in 2 mL ESF media per well were seeded as monolayer in a 6-well plate and 
allowed for attachment for approximately 30 minutes.  In order to check for expression of 
recombinant proteins, 100 μL of P1 virus were then added to each well in the plate and mixed by 
rocking.  After cells were infected for 72 hours at 27°C, due to the secretion signaling peptides, 
protein was secreted to the media.  I pipetted media to wash cell off from the plate and collected 
the supernatant by centrifuge at 500xG for 5 minutes, then saved the cell pellets for intracellular 
expression check. For the cell pellets, I dissolved the pellets with 300 μL lysis buffer, and chilled 
on ice for 15 minutes. Then, centrifuged at 12,000 rpm for 20 minutes at room temperature, to 
separate the soluble and insoluble portion. Next, I collected the soluble protein for protein 
expression check on Western blot. For both the supernatant and the soluble protein portion from 
cell lysate, I checked the protein concentration by using BioRad Protein Assay (BioRad). I 
prepared both secreted protein samples and intracellular protein sample with equal amount of 
protein to load to the 15% SDS-PAGE gel. Protein was then treated with 𝛼-pentaHis antibody 
(Qiagen Cat#34660) then detected on Western blot anti 6x-histidine chemiluminescence Western 
blotting. The first generation of baculovirus (P1) was used to infect Sf9 cells to produce the 
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second generation of baculovirus (P2). The volumes of P1 virus (10 μL and 100 μL) and time 
(72 hours and 96 hours) as two variables has been used to make P2 virus in four 100 mm Tissue 
Culture Plates (BD-Falcon) that seeded with 7.5mL x 106 cells in total volume of 15 mL. The 
first two plates that induced with 10 μL and 100 μL P1 virus were harvested after 72 hours, and 
another two plates also induced with same volume of P1 virus was collected after 96 hours. 
These P2 viruses were used to infect 2 x 106 cells in 2mL ESF-921 per well of 6-well plates, and 
each well added 5 μL, 10 μL, 40 μL and 70 μL of each P2 virus. After 72 hours infection, 
Western blot with 𝛼-pentaHis antibody (Qiagen Cat#34660) were used for protein expression 
check. The lowest volume of virus that produces the highest relative amount of protein is 
designated as the best viral titer and was used as different amounts of the best tittered P2 virus to 
generate higher viral titer (P3) in order for large scale protein expression in Sf9 cells suspension 
culture. The third generation of virus was produced in 150 mm x 15 mm FisherBrandÒ Petri 
Dish (Fisher Scientific) that seeded with 15 x 106 cells in 30 mL ESF and 10% heat inactivated 
HyCloneÒ Fetal Bovine Serum Collected In Central America (Thermo Scientific) at volumes of 
1 μL, 2 μL and 3 μL of the P2 virus (the one found the best titer) for 72 hours and 96 hours. 
Again, I infected 2 x 106 cells in 2 mL media per well in 6-well plates by added 1 μL, 5 μL, 10 
μL and 20 μL of each P3 virus. Incubating for 72 hours, then checked protein expression assayed 
on 𝛼-histidine immunoblot. The best titer has been selected (P3.10.3 72 hours with 10 mL per 
well, 5 μL per 1 x 106 cells), however, this titer was generated from 6-well plates of adherent 
cells. Only half of this volume of virus is needed to infect suspension cells.  The viral titer for 
suspension cells now is 1.25 μL per 1 x 106 cells, and it is ready for large-scale protein 
expression. 
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2.4 Protein purification of antibodies in Sf9 insect cells 
The best titer that selected from P3 virus (P3.10.1 72 hours 1.25 μL per 1 x 106 cells) was 
used to infect 2 x 106/mL cells in 1L flask of 500 mL Sf9 suspension cells. I incubated the cells 
in a shaker at a speed of 105 rpm for 72 hours infection, collected the media to centrifuge at 500 
x G for 5 minutes to harvest the secreted protein from the supernatant, and then purified with Ni 
affinity chromatography at 4°C. Preparing the gravity column of ratio of 1mL Ni Sepharose 6 
Fast Flow (GE Healthcare) slurry per 500 mL suspension cell culture, allows the resin to settle 
then I washed it with 10 column volumes of water, and lastly equilibrated with 10 column 
volumes of 1X lysis buffer (25 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM imidazole).  After 
that, I let all supernatant go through the column (flow through), then washed with wash buffer 
(lysis buffer with additional 12.5 mM imidazole) as same volume as lysis buffer (wash trough). 
Next, I eluted protein in fractions from the column with Elute buffer (lysis buffer with additional 
122.5 mM imidazole); combined the eluted fractions that contain Fab Antibody, and then went 
through the MILLEXÒ-GV 0.22 mm Filter Unit (Millipore) before loading it to size exclusion 
column. Superdex 75 16/60 size exclusion column was connected to ÄKTA (GE Healthcare), it 
has been equilibrated with SEC buffer pH 7.5 (25 mM Tris-HCl pH 8.0, 150 mM NaCl). 
Fraction collector at 2 mL per fraction collected purified protein, and peak fractions has been 
combined and concentrated with 15 kDa-cutoff membrane concentrator (Millipore) to 5 mg/mL. 
Protein was flash frozen in liquid nitrogen and stored at -80°C.  Protein concentration was 
determined by BioRad Protein Assay (BioRad). 
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2.5 Site directed mutagenesis 
In order to increase the selectivity of the metalloantibody to different metals other than 
calcium, I used site directed mutagenesis. Then, I designed primers with the mutations inserted 
to prepare D3032C, D3192H and D3032C/D3192H construct. To design the oligonucleotides, I 
looked at Stratagene quikchange manual, then I used the length between 40-45 bases and for the 
melting temperature (Tm) I used melting temperature greater or equal to 78°C. The primers had a 
minimum GC content of 40%. The formula used to estimate the melting temperature is as 
follows: 
T = 81.5 + 0.41(%GC) − 675/ N − % mismatch 
Where N is the length of the primers. 
 
The forward and reverse primer sequences with the mutagenesis inserts used in the 
pFastBac Dual plasmid is shown in Table IV.1.  
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Table IV.1 Primers sequence, GC content and melting temperature. 
Primer  Sequence 
  From 5’to 3’ 
                            GC 
                            Content 
                     Tm 
D30C-D32C-R 
  
CTGCTGGTACCAGTTCATGCAGTCGCAGATGT
CAGTGGAGGTGATGC  
55.3% 70.3°C 
D30C-D32C-F GCATCACCTCCACTGACATCTGCGACTGCATG
AACTGGTACCAGCAG 
55.3% 70.3°C 
D31H-WT-R GCTGGTACCAGTTCATGTCGTGGTCGATGTCA
GTGGAGGTG 
56.1% 68.8°C 
D31H-WT-F CACCTCCACTGACATCGACCACGACATGAACT
GGTACCAGC 
56.1% 68.8°C 
D92H-R GAACAGAGGCAGGTTGTGGGACTGCAGGCAG
TAGTA 
      56.8% 67.9°C 
D92H-F CTACTACTGCCTGCAGTCCCACAACCTGCCTCT
GTTC 
56.8% 67.9°C 
D31H-CC-F CACCTCCACTGACATCTGCCACTGCATGAACT
GGTACCAGC 
56.1% 69.3°C 
D31H-CC-R GCTGGTACCAGTTCATGCAGTGGCAGATGTCA
GTGGAGGTG 
56.1% 69.3°C 
 
 Synthesized complementary oligonucleotides that has the desired mutation were ordered 
at Integrated DNA Technology (IDT). In order to set up the reaction for polymerase chain 
reaction (PCR), a cocktail that contains: 5μL of 10x reaction buffer, 5μL of 2mM dNTP mix, 
1μL PfuTurbo DNA polymerase, (5, 10, 20, and 50 ng) DNA template, 1μL primers both 
forward and reverse each 100 ng/μL, and double distilled water ddH2O was prepared. For the 
negative control, same cocktail was prepared but this time without PfuTurbo DNA polymerase. 
The PCR was done at BioRad iCycler the denaturing temperature was 95°C for 30 seconds, 
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annealing and elongation steps were done at 95°C for 30 second, 55°C for 1 minute and 68°C for 
2min/kb of plasmid length which for the pFastbac Dual plasmid was about 13 mins with 16 
number of cycles.  
 After the PCR reaction, 1μL DpnI enzyme was added to the PCR tubes and incubated at 
37°C for 30 min. To deactivate the enzyme, the PCR tubes were incubated at 80°C for 20 min 
and the PCR reaction was stored at 4°C. DpnI digests the PCR products of the parental 
supercoiled dsDNA. 
 The mutated plasmid was transformed into DH5𝛼 cells. 1.2 μL of the plasmid was 
pipetted into the DH5𝛼 cell and left on ice for 30 min, 45 second in water bath 42°C and 2 min 
on ice again. I added 250 μL of SOC buffer to the same tube and let it shake in the incubator 
37°C for about one hour. After an hour, the cells were plated on LB-Amp plates and left inside 
the incubator 37°C for 12 hrs. Next day, about 10 colonies on the plates were selected and 5mL 
LB media under sterile conditions were added to the falcon tube with the 5 μl ampicillin 100 
mg/mL and one single colony. The cells were shaking in the incubator for 12 hours. Next day I 
did miniprep to purify the plasmid and sent it for sequencing. The electropherograms are 
presented in the results section of this chapter.  
2.6 Preparing samples for inductively coupled plasma-mass spectrometry (ICP-MS) 
Aliquots of 2.6 mg/mL of LT3015 (LPath, Inc.) and Fab antibody were prepared. 5 
samples (LT3015, Fab antibody, HEPES buffer without CaCl2, HEPES buffer with 10 mM 
CaCl2 dialyzed, and HEPES buffer with 10 mM CaCl2 without dialyzing) were prepared and sent 
for ICP-MS. Aliquots of samples are transferred to 3.5K MWCO dialysis units (Slide-A-LyzerTM 
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MINI Dialysis Unit #88403). 0.1M EDTA solution was prepared and added to the samples and 
dialyzed against 20mM HEPES buffer, 0.22μm filtered, pH 7.2 buffer at 20°C to remove basal 
levels of metals from solution. EDTA is removed by dialysis against 20mM HEPES buffer, 
0.22μm, pH 7.2 for >24 hours with 4 exchanges. Sample concentration is monitored at A280 
using the Nanodrop 2000 (Thermo Scientific) spectrophotometer. The concentration of 
antibodies samples was about 1.45 mg/mL. 100mM stock solutions of CaCl2.2H2O (EMD® 
#401800), are prepared in 20mM NaHEPES, pH 7.2. 200 μL of 100 mM stock solutions of 
CaCl2.2H2O was added to 1.5 mL of Fab, LT3015 and NaHEPES buffer solutions to reach the 
final concentration of 10 mM. The samples were dialyzed against HEPES buffer for >24 hours 
with 4 exchanges. Samples were sent to California State University at Long beach for ICP-MS. 
ICP-MS experiments determine whether the metal selectivity of LT1002 is specific to 
Ca2+ and / or capable of binding other metals. For the selectivity study, we implemented ICP-MS 
technology because of its superiority to absorbance techniques in both sensitivity (measures 
down to parts-per-trillion) and minimization of co-absorbance in final abundance measurement. 
The high temperatures reached with induced-coupled plasma 6,000 K ensure complete ionization 
the particular measured ion in the matrix, limiting the effects of partial ionization and 
atomization of all metal ions in the matrix, allowing for significantly greater detection 
sensitivity. Because mass-spec detects the cations by their mass-to-charge ratio, one can be 
relatively certain that the measured concentration is due to the metal alone and not from other 
interferences as often seen in absorbance detection methods due to co-absorbance or ionization 
suppression effects.  
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Samples were treated with hot HNO3 to precipitate protein and release metals into 
solution. Optionally, samples can be treated by a secondary acid wash procedure including 
perchloric acid. Samples are cooled and centrifuged at 14,000 x rpm for 10min. Supernatant is 
collected. Sample is made ready for ICP-MS by dilution 10-Fold with trace metals grade nitric 
acid and diluted to predetermined volume and mixed before analysis. Samples are analyzed 
within 1-day of digestion.  
Samples are analyzed via Hewlett Packard (Agilent) 4500 Series Inductively Coupled 
Plasma Mass Spectrometer (ICP-MS) by pumping sample through a concentric nebulizer, 
producing a fine sample aerosol. An argon gas carrier carries the sample into high temperature 
radiofrequency argon plasma, which atomizes and ionizes the sample. The ions are extracted 
from the plasma through differentially pumped vacuum interface and separated on the basis of 
their mass-to-charge ratio by a quadrupole mass spectrometer. An electron multiplier detector 
measures the ion concentration of specific mass-to-charge ratio. 
2.7 Preparing samples for microscale thermophoresis (MST)  
 In order to test the metal binding affinities of the antibodies to metals, I used microscale 
thermophoresis instrument. The MST instrument that I have used was NanoTemper technologies 
and the model was Monolith NT.115. The protein samples were labeled with fluorescent dye 
using Monolith NT.115 protein labeling kit red that conjugates to reactive amines. The dye 
carries a reactive NHS-ester group that modifies primary amines as they are present in amino 
acids like lysine.  
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Using the kit manual, different ratio of protein: fluorescence labeled samples were 
prepared and the concentrations were checked with BioRad Protein Assay. The protein 
absorbance was checked at 280nm and dye at 650nm. After selecting the best protein to dye ratio 
(which was the dye concentration 3 times greater than the protein concentration), I ran the 
protein labeled samples on different capillary types. Among all capillaries, hydrophobic 
capillaries were the best ones, where the samples did not stick to the surface of the capillaries 
and the peaks looked great. Also, the tubes were scanned, and the best fluorescence intensity 
achieved with 10-30% LED power. 
The protein and metal samples were diluted in 20mM HEPES buffer. 12 samples were 
prepared, and the protein labeled samples were titrated with MgCl2, CaCl2 and ZnCl2. The metal 
samples titrated to protein had concentrations that increased 10 folds starting from 0 to 104 µM.    
3. Results  
LT1009 (sonepcizumab) is a monoclonal antibody that binds to the signaling lipid 
molecule sphingosine-1-phosphate (S1P).  LT1009 is a fully humanized version of the murine 
LT1002 antibody, and it utilizes light chain CDR loop 1 (CDR-L1) aspartic acid 30, 31, and 32, 
and also light chain CDR loop 3 (CDR-L3) aspartic acid 92 to form metal binding with its 
antigen S1P by utilizing two Ca2+ cations (J. M. Wojciak et al. 2009).  One question we want to 
discover is whether the anti-S1P metalloantibody is metal binding inherent (i.e., encoded at the 
germline level) or is it occurring with the affinity maturation process of antibodies in B cells. 
Using the IgBlast server, we identified three different antibody kappa light chain variable domain 
genes that contain all of the metal coordinated amino acid residues in the corresponding positions 
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of the murine mouse anti-S1P antibody. One of these differed only at four amino acid positions 
from the humanized mouse anti-S1P and so we made the assumption that this gene served as the 
progenitor. In order to test that this antibody precursor possesses innate potential to bind metal 
ions, we attempted to express and purify it and test its metal binding potential in vitro. 
We first attempted expression of the precursor antibody as a Fab fragment in E.coli.  
However, the E.coli cells lack an endoplasmic reticulum for proper protein folding and disulfide 
bond formation of functioning antibodies. Our protein yields were quite low and assessment of 
the size of our E.coli expressed antibodies revealed that they are not correctly assembled.  In 
light of this, we turned our attention to Sf9 cells and baculovirus protein expression system. We 
were able to express and purify well folded Fab antibody and mutated antibody in Sf9 cells.  
3.1 Site directed mutagenesis electropherograms 
   In order to test the metal binding properties of the antibody, I mutated key residues that 
are involved with the metal binding. X-ray crystal structure data has showed us promising result 
of this interaction. By changing aspartic acid 30, 31, 32 and 92 to cysteine and histidine, we were 
able to express and test the metal binding properties of the mutated Fab antibody to Zn2+, which 
is more interesting metal than Ca2+. Metalloproteins that bind to zinc can be found in nature and 
they are involved in many physiological processes. However, finding metalloantibody that 
interacts with metal is novel. Metal increases the binding affinity of the antibody to antigen. 
Specifically, zinc antibody discovery is the original novel outcome. This finding could have a 
potential study area where the binding of the antibody to zinc can selectively increase the 
conjugation of different molecules such as drugs to antibody. Other aspects could be to be used 
as catalytic enzymes.   
91 
Electropherogram indicates the site directed mutagenesis for the CDR loops on the light 
chain of the antibody Fab fragment. The electropherograms are as follows: 
 
Figure IV.2 Electropherogram for D3032C mutations 
 
 
Figure IV.3 Electropherogram for D3192H mutations 
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Figure IV.4 Electropherogram for D3032C/D3192H mutations 
 
3.2 Antibody expression and purification 
500 mL Sf9 suspension culture has been incubated in a shaker for 72 hours at 27°C. 
Proteins secrete in supernatant was collected and went through Ni column purification and eluted 
protein concentrations were determined by Bradford assay and ran on 15% SDS-PAGE gel 
(Figure IV.6).  The most concentrated fractions were combined and filtered. About 2mL of 
protein sample purified by size exclusion chromatography (SEC). The chromatogram shows one 
single peak at 280nm, which indicates the purity of Fab antibody (Figure IV.5). The collected 
fractions were concentrated to 6 mg/mL for 1.5mL, and protein has been frozen and stored at -
80°C.  
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Figure IV.5 Size exclusion chromatography using Superdex 75 16/60 of the His-tagged mutated CHCH Fab 
antibody.  
 
Purification of the mutated CHCH His-tagged Fab antibody using the Ni affinity column 
indicates the expression of both heavy and light chains of the antibody. The 15% SDS-PAGE gel 
is showing the marker lane, lysate, flow through, wash and elution (E1-E6). 
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Figure IV.6 Coomassie-stained 15% SDS-PAGE gel for samples from Ni column purification. The size of Fab 
antibody heavy chain is 26 kDa and the light chain is 24 kDa, and the E2-E4 elutes contain most of the proteins were 
combined. The double bands show heavy and light chains of the antibody.  
3.3 Western blot 
In this expression system, recombinant baculovirus has been used to infect suspension 
culture of Sf9 cells. The viral titer is the main factor for protein yield, and instead of plaque 
assay, we used chemiluminescence western blotting to determine titer. 2 x 106 Sf9 cells with 
2mL media per well were seeded in 6-well plates, and after 72 hours incubation the cells were 
collected, and the concentration of the secreted protein was determined. After finding the best 
transfection from P1 virus, we did P2 virus from different amounts of P1 virus to get better 
protein expression. We also did different incubation time (72 and 96 hr) to find the best titer for 
P2 virus. The best viral titer for P2 virus was P2.10.10 after 72 hour incubation and P2.10.5 after 
96 hour incubation (Figure IV.7 and IV.8).  
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After determining the viral titer for P2 virus, we did expression and purification from 
45x106 cells in 25mL suspension culture with 900 μL and 450 μL of titer virus to compare which 
one is the better titer for suspension culture since the titer we decided above is from adherent 
cells. Ni column purification was conducted to purify the Fab antibody from the two suspension 
cultures. From Bradford assay, the calculated protein yield that was infected with 900 μL virus is 
0.35 milligrams, and the one infected with half of the viral titer is 0.45 milligrams. These results 
prove that the viral titer determined by Western blot is only half of the viral volume needed to 
infect suspension culture for higher protein yield. The amount of virus that have been using for 
protein expression is essential since the viral stock is not reproducible due to accuracy of cell 
counting and exact numbers of virus that need to be added to make the same viral stock.  
Then we moved on to make P3 virus for large suspension culture protein expression. The 
best tittered P2 virus has been used to infect Sf9 cells in the 150mm x 15mm tissue culture plates 
with different amount of virus, after the P3 viruses were made that they have been tested with 
chemiluminescence western blotting for protein. 
 
Figure IV.7 Anti-His Western blot data for secreted mutant CHCH Fab antibody. There were 8 different P2 viruses 
have been made from different amounts of P1 with 72 hour incubation. On the lane 2 of the mutant Fab antibody 
P2.10.10 after 72 hour incubation shows the thickest band. The first 8 lanes are indicating secreted reduced 
antibodies and the second 8 lanes are showing non-reduced antibodies.   
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Figure IV.8 Anti-His Western blot data for secreted mutant CHCH Fab antibody. There were 8 different P2 viruses 
have been made from different amounts of P1 with 96 hour incubation. On the lane 2 of the mutant Fab antibody 
P2.10.5 after 96 hour incubation shows the thickest band. The first 8 lanes are indicating secreted reduced antibodies 
and the second 8 lanes are showing non-reduced antibodies.   
 
Figure IV.9 Anti-His Western blot data for secreted mutant CHCH Fab antibody P3 virus expression check. P2 
virus has been used as control to provide more reliable results. There were 10 different P3 viruses have been made 
from different amounts of P2 virus. Panel A. is indicating the incubation time after 72 hour and panel B is 
incubation after 96 hour. Comparing to the control P2 virus from panel A. and B. P3.3.5 is the best among P3 
viruses.  
 
 
After checking the expression of the protein with different viruses, we did a large scale 
about 500 ml media and purified the secreted proteins through Ni column and ÄKTA. I had used 
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about 2mg of the protein ICP-MS to test the metal binding properties of the mutant antibody to 
different metals. Among all of the mutated antibody, D3032C/D3192H antibody was the 
promising mutant one that binds to zinc. The other mutant antibodies did not show any 
significant binding to other metals such as Cu2+, Co2+, and Ni2+. In order to test and confirm 
binding of the mutated CHCH Fab antibody to zinc, I constructed two methods: Microscale 
thermophoresis and Inductively coupled plasma mass spectrometry.  
3.4 Inductively coupled plasma-mass spectrometry (ICP-MS) 
Binding of CHCH mutated Fab murine monoclonal antibody to zinc have been analyzed 
using ICP-MS. Figure IV.10 shows the binding of CHCH Fab fragment antibody to Zn2+ and the 
zinc concentration is greater than the controls. Negative controls are HEPES buffer in the 
presence of Zn2+ and dialyzed overnight which is showing negligible amount of Zn2+ and HEPES 
buffer with Zn2+ without dialyzed is showing great amount of Zn2+. From this data we can 
conclude that Fab monoclonal antibody binds to Zn2+. 
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Figure IV.10 ICP-MS data for CHCH mutant Fab antibody.  Sample 1 is HEPES buffer without Zn2+. Sample 2 is 
HEPES buffer with 10mM Zn2+ dialyzed. Sample 3 is HEPES buffer with 10mM Zn2+ without dialyzing.  Sample 4 
is mutant CHCH Fab antibody with 10mM Zn2+ dialyzed.  
3.5 Microscale thermophoresis (MST) 
Another method that I used to determine the binding affinity of CHCH mutant Fab 
antibody to zinc was MST. MST is a technology for the biophysical analysis of interactions 
between biomolecules. It is based on the principle that molecules move along a temperature 
gradient in a capillary. MST signal is plotted against the ligand concentration to obtain a dose-
response curve, from which the binding affinity can be deduced. 
The fluorescence samples were prepared, and I used hydrophobic capillaries. Then, ZnCl2 
was titrated to the protein samples. The first titration did not have ZnCl2 but the concentration of 
Zn2+ increased 10-fold up to 104 μM. I had a total of 12 samples (Figure IV.11). 
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Figure IV.11 MST data for CHCH mutant Fab antibody. Samples were prepared in 20mM HEPES buffer and 
labeled with the fluorescent dye using Monolith NT.115 protein labeling kit red that conjugates to reactive amines. 
The first sample was titrated without Zn2+ and the rest of the samples were titrated with Zn2+ that their concentration 
increased by 10-fold up to 104 μM. The binding affinity (KD) calculated for this experiment was 168 μM.  
 
3.6 Other metalloantibodies in nature 
Other metalloantibodies (e.g. Q425 and 2C10) introduced in Chapter II of this 
dissertation have the same sequence on their CDRL1-L3 loops as the precursor antibody. This 
indicates the same binding site on their CDR loops to antigen in the presence of metal ions. 
Murine 2C10 antibody binds to double stranded DNA (dsDNA) as its antigen.  
It was interesting that anti-dsDNA antibodies were found in serum of patients with 
Systemic Lupus Erythematosus (SLE). SLE  is a disease that occurs when the body's immune 
system attacks healthy connective tissue cells (Y. J. Jang and Stollar 2003). On top of that, Q425 
binds to CD4 that protects against HIV infection and requires calcium for recognition of CD4 (T. 
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Zhou et al. 2005). However, the binding site of Ca2+ is different form the binding site of 
humanized LT1009 antibody with S1P antigen and Fab LT1009 antibody without antigen and in 
the presence of Ca2+. 
 We were interested in (i) finding the epitope of CD4 to Q425. We also aimed to explore 
(ii) if our antibody large scale expression system is able to produce Q425 and 2C10. 
Furthermore, we were interested in (iii) testing whether 2C10 binds to dsDNA in the presence of 
metal or not, and (iv) does the metal have any effect in the antibody: antigen binding affinity, 
since they all have the same homology in their CDR loops of their light chain.  
To achieve these goals, I mentored two undergraduate students, Sally Luong and Citlayi 
Villasenor, in this project in order to perform expression and purification of these antibodies.  
The protein expression method used for Q425 and 2C10 were the same as precursor 
antibody. The Western blot data indicates that both antibodies were expressed but the expression 
level was lower than the precursor. We were able to use about 2-3 mg of the antibody to do 
further analyzing such as MST and pull down assays.  
3.7 Western blot 
The same method was used to express Q425 and 2C10 antibodies. For the best titer, we 
have used P3 virus and the expression levels were checked with Western blot. The Western blot 
data indicates both the expression of Q425 and 2C10 antibody after 96 hours. The size of the 
antibodies for the denaturing (part A) was 25 kDa and for the non-denaturing (part B) was 50 
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kDa. The best viral titer for P3 virus for Q425 was P3.1.5 and for 2C10 was also P3.1.5 after 96 
hours incubation time (Figure IV.12).  
 
Figure IV.12 Anti-His Western blot data for secreted Q425 and 2C10 antibody. There were 8 different P3 viruses 
have been made from different amounts of P2 with 96 hour incubation. From lane 1 was the control P2 and from 
lane  2-9 is Q425 antibody and from 11-16 is 2C10 antibody expression check. Part A is indicating the non-reduced 
antibody expression level and part B is indicating the reduced expression level. 
3.8 Pull down assay 
In order to determine if Q425 binds to CD4 with or without Ca2+, Citlayi Villaseñor, did a 
polyHis-tagged pull down assay and ran murine monoclonal Q425 antibody and CD4 antigen 
with and without Ca2+ on Ni sepharose beads. The His-tagged Q425 binds to the Ni beads and 
the unbound protein was washed away. By adding CD4 protein to the immobilized Q425 protein 
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the complex was formed, and the unbound protein was washed away. We have test this in the 
presence of 10mM Ca2+ and without Ca2+. To elute Q425: CD4 complex she used Protein 
loading dye and SDS solution. The samples were collected at each step and prepared for Western 
blot. The primary antibody used was anti-CD4 antibody which can detect CD4 and the secondary 
antibody was goat anti-mouse antibody that can detect mouse Q425.     
The Western blot data using anti-CD4 antibody and anti-mouse antibody indicates that 
Q425 binds to CD4 in the presence of Ca2+  in 0.5% Triton-X buffer (Figure IV.13). The 
molecular weight for the His-tagged heavy chain Q425 antibody is 25 kDa and for CD4 is 55 
kDa.  
 
Figure IV.13 Anti-CD4 Western blot data. Lane 1 is CD4, lane 2 is Q425, lane 3 CD4 and Ca2+ in wash, lane 4 CD4 
with Ca2+ in elution, lane 5 Q425 with CD4 in wash, lane 6 Q425 and CD4 in elution, lane 7 Q425 with CD4 and 
Ca2+ wash, lane 8 Q425 with CD4 and Ca2+ elution.   
 
 
Ca2+ - - +      +    - - +      +
CD4 +      - +     +    +     +      +      +
Q425 - +      - - +     +      +      +
1      2     3     4    5    6     7    8
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3.9 Microscale thermophoresis (MST) 
Anti-dsDNAs are used in blood tests in diagnostic laboratories. Analytical technique like 
immunofluorescence used to detect anti-dsDNA antibodies  (Mortensen, Fenton, and Rekvig 
2008; Solomon et al. 2002). Anti-dsDNAs are highly diagnostic for SLE disease. To determine if 
the presence of metal has an effect on binding affinity of 2C10 to dsDNA, I used MST to 
confirm the binding of 2C10 to dsDNA in the presence of Ca2+, Mg2+ and dsDNA. I ran three 
different MST experiments: First I used 2C10 antibody titrated to dsDNA and Ca2+ and measured 
the binding, second, I titrated 2C10 antibody to dsDNA and Mg2+, and third I titrated 2C10 
antibody to dsDNA. The results indicate that metal increases the binding affinity of 2C10 to 
dsDNA and Mg2+ increases the binding affinity slightly (Figure IV.14-16). The protein: 
fluorescence dye ratio that I used was 1:3 ratio. To each 2C10 antibody samples Gbp3 14-mer 
dsDNA was titrated that had a concentration about 4,162 ng/μL. For one of the MST experiment, 
I titrated Ca2+ to the samples starting from zero to 102 μM and another one I titrated Mg2+ to the 
samples starting from zero to 102 μM. 
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Figure IV.14 MST data for 2C10: dsDNA: Ca2+. Samples were prepared in 20mM HEPES buffer and labeled with 
the fluorescent dye using Monolith NT.115 protein labeling kit red that conjugates to reactive amines. All sample 
was titrated with same amount of 2C10 and dsDNA and Ca2+ was titrated to the samples and Ca2+ concentrations 
increased by 10 folds in each sample. The binding affinity (KD) calculated for this experiment was 0.256 μM.  
 
 
Figure IV.15 MST data for 2C10: dsDNA: Mg2+. Samples were prepared in 20mM HEPES buffer and labeled with 
the fluorescent dye using Monolith NT.115 protein labeling kit red that conjugates to reactive amines. All sample 
was titrated with same amount of 2C10 and dsDNA and Mg2+ was titrated to the samples and Mg2+ concentrations 
increased by 10 folds in each sample. The binding affinity (KD) calculated for this experiment was 0.10 μM.  
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Figure IV.16 MST data for 2C10: dsDNA. Samples were prepared in 20mM HEPES buffer and labeled with the 
fluorescent dye using Monolith NT.115 protein labeling kit red that conjugates to reactive amines. All sample was 
titrated with same amount of 2C10 and dsDNA. The binding affinity (KD) calculated for this experiment was 1.63 
μM.  
 
4. Conclusion and future direction 
 There is a homology between humanized LT1009, Q425, and 2C10 antibody CDR 
sequence of their light chain. Therefore, we prepared precursor antibody that has the same 
sequence on their CDRL1-L3 loops. X-ray crystallography data indicates that LT1009 antibody 
binds to S1P antigen in the presence of metal. The binding affinity gets 10 times greater in the 
presence of Ca2+ (J. M. Wojciak et al. 2009). We were interested to determine if these 
metalloantibody binds to other metals instead of Ca2+. Therefore, I expressed and purified Fab 
precursor antibody and with site directed mutagenesis I changed the amino acids that were 
involved in the binding site. I prepared three different constructs, which where D3032C, D3192H 
and D3032C/D3192H. The large scale expression and purification of these construct went well 
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and I was able to get 8-10 mg of the mutant antibodies from 500 mL culture. After that, I tested 
to see if mutant antibody binds to Cu2+, Zn2+, Co2+ and Ni2+. Among all mutant 
D3032C/D3192H interacted to Zn2+. To confirm this, ICP-MS data indicated that this construct 
binds to Zn2+ compared to negative controls and also MST data showed good binding curve of 
the labeled mutant antibody to Zn2+. The KD for this binding was about 168 μM.  
We were also able to express both antibodies Q425 and 2C10 large expression using 
baculovirus and Sf9 insect system. Both heavy and light chains were expressed with our Sf9 
tissue culture system. MST data indicated that metal has a small effect on 2C10: dsDNA binding 
affinity. To further analyze this, Citlayi Villasenor, is going to do gel shift assay to determine the 
binding of dsDNA to 2C10 antibody with and without metal. The pull down assay data indicates 
that Q425 binds to CD4 in the presence of Ca2+ in the Triton-X buffer. Further analysis is 
necessary to determine the epitope mapping of CD4 to Q425 antibody.  
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Chapter V 
Conclusion and Discussion 
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There are many different examples of metalloproteins in nature that were studied before, 
but what is novel is the fact that metal has an effective role in stabilizing the binding interaction 
between the antibody and antigen in metalloantibodies.  
We were interested in studying this class of antibodies to find answers to the following 
research questions: (i) Can LT1009 antibody bind to Ca2+ independent of antigen? (ii) Can 
LT1009 antibody bind to any other metal ions? (iii) Are their other examples of antibodies that 
employ this use of metals as bridging ligands in antigen binding? (iv) Did LT1009 metal binding 
develop during maturation or is it present in germline variable domain gene sequences? (v) Can 
we engineer specificity toward metals other than Ca2+? 
In order to answer all these questions and be able to do routine mutagenesis and 
purification of antibodies for binding structural studies, we needed a large scale expression 
system to express and purify antibodies, but first let’s summarize the previous literatures.  
Previously, murine LT1002 antibody has been reported as an antibody that binds 
specifically to sphingosine-1-phosphate as an antigen (O’Brien, Jones, et al. 2009). Later on, in 
Dr. Huxford’s lab we crystallized LT1009 humanized version of LT1002 antibody in the 
presence of metal and sphingosine-1-phosphate as a lipid antigen. X-ray crystal structure and 
ICP-MS data indicated that Ca2+ has a great effect in stabilizing S1P:LT1009 interaction. The X-
ray crystallography has distinguished two Ca2+ ions in coordination with CDRL1-L3 loops of 
LT1009 and S1P (J. M. Wojciak et al. 2009). Furthermore, another group at the national institute 
of health reported that murine Q425 antibody has interaction with CD4 as an antigen. The X-ray 
crystal structure has shown that this antibody has the potential to cure HIV. Also, in their crystal 
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structure, Ca2+ and Ba2+ has an effective role in stabilizing the interaction between CD4:Q425 
(T. Zhou et al. 2005). However, the binding site of Ca2+/Ba2+ is different from LT1009 binding 
site to Ca2+.  
In order to find out whether LT1009 antibody binds to Ca2+ independent of antigen or 
not, we have crystallized LT1009 antibody with Ca2+ in the absence of S1P. 2.8 Å X-ray crystal 
structure shows that LT1009 binds to Ca2+ without S1P, and metal coordination dimensions at 
the binding site are slightly greater in comparison with the presence of S1P.  
By searching the IgBlast server we found the metal binding coordination site sequence of 
the CDRL1-L3 loops of LT1009 antibody homology in other species such as rat, human, monkey 
and mouse antibodies. Using the IgBlast server, we found the variable domain genes that most 
closely matched to the mouse anti-S1P antibody, and we designed the heavy and light chain 
precursor plasmid of the Fab antibody.  
First, I used E.coli (BL21(DE3) and T7 shuffle cells) to express the antibodies but I 
observed low expression yields, such that the protein concentration was not enough for further 
analysis assays. The purification of the antibody had some difficulties either. After purifying it 
from Ni affinity column, I used size exclusion chromatography to do the second step of 
purification and observed that always the peaks from SEC were two separate peaks that were 
exactly identical on SDS-PAGE gel (Figure V.1).  
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Figure V.1 SEC and SDS-PAGE gel data for the precursor antibody expression in E.coli. Size exclusion 
chromatography shows two peaks at the purification step and 15% SDS-PAGE gel shows that both peaks show at 
the same place on the gel.  
 
To find out which peak is which, I performed size exclusion chromatography with multi-
angle light scattering to identify the molecular weight of the protein in solution independent of 
its antigen. Therefore, I separately ran the peaks on SEC-MALLS and the results indicated that 
one of the peaks was 50 kDa and another one was 25 kDa. By running the standard LT1009 
antibody that Lpath, LLC has provided us, we found out that LT1009 Fab antibody ran at 25 
kDa. One of the precursor peaks molecular weight was double the size of the other peak. This 
could be because of dimerization of the antibody and not being properly folded.  
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Figure V.2 Size exclusion chromatography with multi-angle light scattering data for the precursor antibody 
expression in E.coli. Chromatogram A shows the first peak molecular weight 50 kDa, chromatogram B shows the 
second peak molecular weight 25 kDa and chromatogram C shows the molecular weight of Fab LT1009 25 kDa.  
 
After that, we looked at eukaryote cells to express the antibody. We followed the 
procedure in an article in the literature that suggested to use pFastBac dual plasmid with gp64 as 
a signal peptide (Furuta et al. 2010). Then, I started to clone pFastBac dual plasmid with the 
heavy and light chains inserted in the plasmid with the p10 promoter used for the light chain, pH 
promoter used for the heavy chain and gp64 signal peptide at the beginning of each chain. Next, 
I used our Sf9 insect system facility to express the antibody. The first Western blot from P1 virus 
seemed promising. Then, I got P2 and P3 viruses in order to get better yield of antibodies. After 
protein expression and purification, I was able to get about 8 mg/mL protein from 500 mL of 
media.  
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Then, we performed ICP-MS analysis to test the metal binding properties of the precursor 
antibody to Ca2+ in the absence of antigen. The data indicated that the precursor antibody binds 
to Ca2+ much greater than the control LT3015 antibody that does not bind to metal.  
I then tried to alter the residues involved in the binding site of the LT1009 antibody in 
coordination with Ca2+ and S1P antigen. I tried to prepare 3 mutants with different mutations on 
the binding site. The residues on the binding sites of CDR-L1 and CDR-L3 loops were Asp30, 
Asp31, Asp32 and Asp92. By mutating these residues to D3032C, D3192H and finally 
D3032C/D3192H, we wanted to test to see if the mutant antibodies bind to any other metals 
instead of Ca2+. We also wanted to see if the new mutant antibodies can be used as catalytic 
enzymes. Therefore, I dialyzed the new mutant antibodies with 10 mM of Co2+, Zn2+, Ni2+ and 
Cu2+ and sent the results to ICP-MS data at California state, Long Beach. The results indicated 
that the mutant D3032C/D3192H binds to Zn2+. I further tested the binding of the fluorescence 
mutant antibody to Zn2+ and looked at its binding curve using MST. The binding curve looks 
good with a KD value to be 168 μM.  
Another antibody found in nature that we were interested in studying is Q425 and 2C10 
antibody. Both are murine antibodies that have the same homology in their CDRL1-L3 loops. By 
using MST, the fluorescence murine 2C10 antibody showed that metal increases the binding 
affinity of the antigen: antibody interaction. MST data also indicates that Mg2+ (KD=0.10 μM) 
has greater effects than Ca2+ (KD=0.256 μM) in the binding affinity.  
Finally, we concluded that the homology found in metalloantibodies CDR loops in 
different species from mouse, rat, human and monkey indicates that the metal binding is present 
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in the germline variable domain gene sequences of the antibodies. Also, the mutant 
metalloantibody binds to Zn2+ by the mutation of the CDR loops to D3032C/D3192H.  
In conclusion, the metal binding ion motif can be used as a highly selective site for 
specific conjugation, which the cysteine reactivity can be protected against O2 in the presence of 
metals. This site-specific conjugation strategy can be used for antibody-drug conjugates. This 
metalloantibodies can stabilize and increase the affinity of the antibody to different antigens. In a 
different study, the human light chain of A18b antibody was characterized and was capable of 
enzymatic activities like hydrolyzing vasoactive intestinal polypeptide and nucleophilic 
properties (V. Sharma et al. 2009). This indicates that the metalloantibody can be used in 
biotechnology as future engineered catalytic metalloantibodies.  
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